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Experience is the name everyone gives to their mistakes 
Oscar Wilde 
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1.INTRODUCTION 
1.1 ATHEROSCLEROSIS 
The word atherosclerosis is derived from the Greek meaning both softening (athere) and 
hardening (skleros) and refers to a complex disease process affecting the major blood vessels 
of the body. It is a disease that has plagued humans for centuries.  
1.1.1 HISTORY  
It was not until the mid-seventeenth century that a process that resulted in degeneration of the 
arteries with advancing age was recognized. In 1755, the Swiss physiologist Albrecht von Haller 
reported on progressive atherosclerotic changes in the blood vessels of the elderly[1]. Later, in 
1761, the Italian physician and pathologist Giovanni Battista Morgagni heralded the idea of 
using microscopic evaluation of tissues to correlate disease with histology. His work, and that of 
his pupil Antonio Scarpa, correlated a lesion that they described as similar to an ulcerated 
plaque to aneurysm formation[2]. Thus, atheromatous lesions became the focus of study—first, 
as a precursor to aneurysm formation, and then, as a separate pathologic entity. Later, a 
surgeon, Joseph Hodgson, in London proposed that inflammation was the underlying cause of 
these plaque formations and hypothesized that the process was linked to the intimal layer of 
blood vessels. Rokitansky was one of the first to observe and document that there were both 
thrombogenic and calcific components in atherosclerotic lesions[3]. Rudolf Virchow concluded 
that atherosclerotic lesions were located in the intimal layer and described the process of plaque 
formation that was initiated by the formation of a coagulum which he called thrombus. The 
studies of Alexander Ignatovski and Nikolai Anitschkovin the early 1900s demonstrated that 
atherosclerotic changes could be induced in animals by a diet rich in cholesterol[4]. This led to 
the important discovery in 1910 by German chemist Adolf Windaus that human atherosclerotic 
lesions contained cholesterol. 
HISTORICAL EVOLUTION OF THE UNDERSTANDING OF VASCULAR DISEASE
NAME YEAR CONTRIBUTION
Andreas Vesalius and Gabriel 
Fallappio
1550s Described aortic and peripheral aneurysms
William Harvey 1628 Described cardiovascular system as a circuit
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1.1.2 EPIDEMIOLOGY 
Atherosclerosis is the principal cause of heart attack, stroke, and peripheral vascular disease 
and remains a major contributor to morbidity and mortality in the Western World.  
Cerebrovascular disease is also a major consequence of the atherosclerotic process. Stroke, 
with an incidence of 500,000 cases yearly, is the third leading cause of death in the US. In one 
study, the annual stroke rate was determined to be 1.3% per year in patients with up to 75% 
carotid stenosis and the rate of stroke is nearly tripled in patients with higher-grade lesions[5]. 
Thus, the results of untreated or poorly treated atherosclerotic disease has significant medical 
consequences. 
1.1.3 ETIOPATHOGENESIS 
Disease progression is slow, beginning in childhood and usually becoming clinically manifest in 
middle age or later. Although the aetiology of atherosclerosis is not fully understood, it is 
generally accepted that atherosclerosis is a multifactorial disease induced by the effects of 
various risk factors on appropriate genetic backgrounds. Many risk factors, such as 
hypercholesterolemia, modified lipoproteins, hypertension, diabetes, infections and smoking 
have been identified in the development of atherosclerosis.  
Atherosclerosis has been the focus of intense research for over 100 years. Since Anitschkow 
and Chalatow first reported that cholesterol can cause atherosclerosis, many investigators have 
Daniel Sennet 1628 Described arteries as comprised of two concentric layers
Albrecht von Haller 1755 Described progressive changes within arterial walls
Giovanni Battista Morgagni 1761 Described microscopic changes occurring within atheromas
Antonio Scarpa 1804 Correlated ulcerated atheromatous lesions with aneurysmal development
Joseph Hodgson 1815 Proposed inflammation as a cause of atherosclerosis
Jean Lobstein 1829 Coined the term arteriosclerosis
Carl Rokitanski 1852 Detailed descriptions of early and mature atheromatous plaques
Rudolf Virchow 1854 Described the process of thrombosis and embolism
Alexander Ignatovski 1908 Experimentally induced atherosclerosis in rabbits
Adolf Windaus 1910 Discovered cholesterol within atherosclerotic lesions
Nikolai Anitschkov and Ludwig 
Aschoff
1933 Provided summaries of early experimentation and results regarding the 
research of atherosclerosis
NAME YEAR CONTRIBUTION
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intensively studied the role of blood cholesterol in the pathogenesis of atherosclerosis. New 
insights into the pathogenesis of atherosclerosis have emerged during the last decades, due to 
the progress of cellular and molecular approaches to the study of cell interactions in the arterial 
wall as well as alterations of lipid metabolism. More recently, a widely accepted hypothesis is 
that atherosclerosis is an inflammatory disease, because recent advances in the basic science 
have established a fundamental role for inflammation in mediating all stages of this disease from 
initiation through progression and, ultimately, the thrombotic complications of atherosclerosis[6].  
In summary, atherosclerotic vascular disease is a chronic inflammatory disease of arteries 
characterized by the invasion, proliferation and accumulation of cells from the arterial media 
(smooth muscle cells) and the circulating blood (monocytes/macrophages and T lymphocytes) in 
the intimal layer, with deposition of connettive tissue and lipids. This disease is characterized by 
accumulation of low-density lipoprotein in the arterial intima, expression of leukocyte adhesion 
molecules and chemokines by activated endothelium, promoting the recruitment of innate and 
adaptive immunity cells (monocytes and T cells) to the intima, thus resulting in local 
inflammation process. Inflammation and increased oxidative stress play important roles in the 
pathogenesis of atherosclerosis and plaque instability[7-9]. Therefore, human atherosclerosis 
can be considered both a metabolic and an inflammatory disease. 
1.1.4 ARTERIAL WALL AND PLAQUE DEVELOPMENT 
The intima of large and medium sized arteries is composed of a monolayer of endothelial cells 
and matrix proteins and occasional smooth muscle cells in the subendothelial space. The media 
of the vessel contains smooth muscle cells and the elastic lamina built by matrix proteins, while 
the main component of adventitia is connective tissue. With increasing age, the diseased arterial 
wall slowly thickens and develops focal lesions of lipid accumulation in the intima. These early 
lesions are known as fatty streaks and are thought to be the sites of predisposition to advanced 
lesions called atherosclerotic plaques or atheroma, which may lead to clinical symptoms in 
certain circumstances. The atherosclerotic plaque or atheroma is the advanced lesion and 
consist of a dense accumulation of extracellular lipid, known as the lipid core, occupies an 
extensive but well-defined region of the intima[10]. No increase in fibrous tissue and 
complications such as defects of the lesion surface and thrombosis are present at this initial 
stage of disease. The characteristic core appears to develop from an expansion and confluence 
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of the small isolated pools of extracellular lipid that characterize atheroma. Between the lipid 
core and the endothelial surface, the intima contains macrophages, smooth muscle cells, 
lymphocytes and mast cells. Capillaries surround the lipid core, particularly at the lateral margins 
and facing the lumen. Frequently macrophages, macrophage foam cells, and lymphocytes are 
more densely concentrated in the lesion periphery. Much of the tissue between the core and the 
surface endothelium corresponds to the proteoglycan-rich layer of the intima, although infiltrated 
with the cells just described. Advanced lesions may or may not narrow the arterial lumen, nor be 
visible by angiography, nor produce clinical manifestations. Such lesions may be clinically 
significant even though the arterial lumen is not narrowed, because complications may develop 
suddenly[10].  
In addition, two types of atherosclerotic plaques, i.e. ‘vulnerable’ and ‘stable’ plaques, have been 
recognized[8]. Vulnerable plaques often have a well-preserved lumen, since plaques remodel 
outward initially. The vulnerable plaque typically has a substantial lipid core and a thin fibrous 
cap separating the thrombogenic macrophages bearing tissue factor from the blood. Clinical 
data suggest that stable plaques more often show luminal narrowing detectable by angiography 
than do vulnerable plaques, but with much less chance of rupture.  
1.1.5 RISK FACTORS 
Accumulating evidence suggests a causal relationship between blood cholesterol and 
atherosclerosis. It is established that familial hypercholesterolemia related to increased LDL 
levels causes premature atherosclerosis and heart disease[11], whereas non-genetic 
hypercholesterolemia is also associated with the development of atherosclerosis.  
Hypertension is another well-established risk factor for atherosclerosis[12]. Clinical trials have 
shown that, in the highest quintile for diastolic pressure, hypertension still contributes 
significantly to the risk of atherosclerosis, even with the added risks of high cholesterol and 
smoking. The fact that atherosclerotic lesions preferentially occur in the areas where 
hemodynamic or biomechanical stress is altered, e.g. bifurcation of the arteries, supports the 
idea that hypertension exerts its role in the pathogenesis of atherosclerosis via altered 
mechanical stress to the vessel wall. Although veins do not develop spontaneous 
atherosclerosis-like lesions, accelerated atherosclerosis occurs rapidly in venous bypass grafts, 
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which bear increased biomechanical forces due to alterations in blood pressure, i.e. vein (0-30 
mm Hg) vs. artery (120 mm Hg). This finding supports the hypothesis that mechanical stress 
could be a crucial factor in the pathogenesis of atherosclerosis.  
As mentioned, atherosclerosis is a highly prevalent disease in humans with significant morbidity 
and mortality[13] and is one of the leading cause of death and one third of population have 
some form of the disease, which includes coronary disease, cerebrovascular disease and 
peripheral artery disease[14]. However, half of those with the disease do not have traditional 
cardiovascular risk factors such as obesity, hypercholesterolemia, hypertension, history of 
smoking or genetic background[15], and thus the cause(s) of rapid atherosclerotic plaque 
progression and disease is unknown in many patients. Traditional risk factors only explain a 
proportion of the incident cases of all atherosclerosis. There is a body of evidence that 
microorganisms play a role in the pathogenesis of atherosclerosis and may be a primary risk 
factor in people who do not suffer from other established risk factors.  
1.1.6 INFECTIOUS HYPOTHESIS 
The infectious hypothesis of atherosclerosis has been studied for some decades. Assuming 
involvement of both innate and adaptive immune systems in atherogenesis, infections with 
bacteria and/or viruses have been supposed to potentially contribute to the pathogenesis of 
atherosclerosis via direct and indirect mechanisms.  
Infectious agents represents a major source of systemic inflammatory response activation with 
the potential to accelerate plaque growth and instability[16]. There is a substantial evidence 
demonstrating an association between the induction of inflammatory responses induced by 
infectious agents and the acceleration of atherosclerosis[14, 16-19] and it has been postulated 
that chronic infections can contribute to the development of atheroma by direct (platelet 
aggregation, invasion of endothelial cells and endothelial injury) and indirect (induction of 
intracellular adhesion molecules, production of antibodies to lipopolysaccharide as well as 
cytokines and disfunction of the immune system) mechanisms[20]. Several microorganisms 
including Chlamidia Pneumoniae and cytomegalovirus have been reported to be implicated in 
the infectious etiology of atherosclerosis[21]. However, the data are inconsistent, with other 
studies showing no increased risk for atherosclerosis[22, 23]. One possible explanation for this 
 8
disparity is that infections contributing to atherosclerosis risk may depend, at least in part, on the 
host’s response to the pathogen, i.e. inflammatory and immune reactions.  
Among the various infectious agents, periodontal pathogens are prominent contenders in the 
infectious hypothesis because of the chronic inflammation associated with periodontal disease. 
There is also a significantly increased prevalence and incidence of coronary artery disease 
indicating that periodontal disease predicts coronary artery disease[24]. Although there are over 
500 bacterial species in the oral cavity, probably only a few species are implicated in the 
progression of periodontal disease.  
1.2 PERIODONTAL DISEASES 
Periodontal diseases are complex multifactorial diseases caused by polymicrobial subgingival 
biofilm with immune and inflammatory responses. The polymicrobial nature of periodontal 
disease promotes chronic inflammation and orchestrates a complex disease mechanism in 
which inflammation results in the destruction of the periodontium (alveolar bone, cementum, 
periodontal ligament and gingiva). It has been recently revealed that induction of periodontitis is 
actually more complex and involves the entire microbial community present in the oral cavity. 
Periodontal inflammation is thought to be largely mediated by ‘pathobionts’ which are 
commensal organisms that under conditions of disrupted homeostasis (i.e. during P. gingivalis 
infection) have the potential to deregulate the inflammatory response and cause disease[25].  
1.2.1 PERIODONTAL AND CARDIOVASCULAR DISEASE RELATION 
Given the high incidence of periodontal and cardiovascular diseases and their economic cost to 
society, defining their mechanistic link has become increasingly important. This is illustrated by 
the increasing number of reports published on the link between periodontal disease and 
cardiovascular disease in recent years; in 2007, only 73 articles were cited on this topic; 
however, by 2014 there were close to 4000[26]. 
The story begins in 1989 when two Scandinavian reports revived a century-old hypothesis 
relating chronic infections with vascular disease that originally was proposed by French and 
German scientist[27, 28]. Mattila and colleagues[29] found high markers of oral infections more 
frequently in patients with recent myocardial infarction than in health control patients. Syrjanen 
and colleagues[30] observed relatively poor oral health among patients who had experienced a 
recent stroke compared with control patients who had not experienced stroke. These authors 
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drew careful conclusions, primarily because of the substantial overlap noted between risk 
factors for both periodontal disease and cardiovascular disease: being older, being male, 
cigarette smoking, diabetes and low socioeconomic status. If periodontal disease and 
cardiovascular disease simply share common risk factors a correlation between the two would 
be expected even if a causal link did not exist. The geographical homogeneity and small number 
of patients enrolled in these early studies precluded any reliable generalizations beyond the 
specific study population. Subsequently, studies addressing many of these limitations have 
made substantial contributions to clarify the association[31, 32]. Many studies reported positive 
associations after accounting for the effects of multiple risk factors such as age, sex, diabetes, 
cholesterol levels, blood pressure, obesity, smoking status, dietary patterns, race, education and 
socioeconomic status[33-37]. These results have particular importance in the case of smoking 
but there is the possibility of an health bias effect, in which people who smoke are more likely to 
have unhealthy lifestyles, which can lead to both periodontal and cardiovascular diseases. Grau 
and colleagues[38] provide important information concerning the specificity of the hypothesis to 
periodontal disease; they reported a 400 percent increase in stroke risk associated with 
periodontitis but found no relationship between caries and strokes. These findings argues 
against a healthy lifestyle bias. Not all studies have found a positive relationship between 
periodontal and cardiovascular disease. Reports from the Health Professional Follow-Up 
Study[39] and the Physicians’ Health Study[40] observed no association between periodontal 
disease and either coronary artery disease or stoke among more than 66000 male health 
professionals. The large sample sizes provide a good reason for caution but a major limitation of 
these studies stems for the self-reported nature of periodontal disease assessment. 
Interestingly studies reporting no association between periodontal disease and coronary disease 
are at odds with stroke findings from the same population. These discrepancies are consistent 
with the literature, which indicates that periodontal disease might be a stronger risk factor for 
cerebrovascular disease than for coronary disease[28, 31]. 
Reports from the United States[37] and Germany[38, 39] have provided evidence that the 
association between periodontal disease and cardiovascular disease might be stronger among 
men than among women. The possibility that novel risk factors might partly explain some of the 
sex differential in cardiovascular disease is intriguing[41].  
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In summary, since 2003, research supports a moderate relative association between 
cardiovascular disease and periodontal disease[31, 32]. This relationship appears to be more 
pronounced in younger participants, possibly different in male and female subjects and 
consistently stronger for clinical stroke outcomes. Nevertheless, substantial variation in results 
among studies is apparent and other research designed to measure oral infection exposure and 
mechanisms that link with atherosclerosis were needed[28].  
During the period between 2003 and 2006, four separate large clinical trials were designed to 
treat coronary artery disease patients with antibiotics to alleviate disease progression, although 
these agents were not specific for periodontal pathogens[42-45]. The results from these trials, 
each of which enrolled over 4000 patients with coronary artery disease, showed no significant 
long-term benefit of antibiotic treatment in those with established disease. Following the 
publication of the results of these separate studies, interest in further examining the link between 
infection and cardiovascular disease considerably declined.  
As already mentioned the study of periodontal disease and cardiovascular disease association 
has its roots in the broader hypothesis concerning infections and cardiovascular disease. 
Therefore recent research has provided new insights by obtaining more precise measures of 
exposure to periodontal microbes.  
Many studies demonstrated that periodontal disease-associated bacteria enter the blood stream 
during mastication, brushing and flossing teeth and during dental procedures[46]. Dental plaque 
has been considered as the reservoir of the most pathogenic bacteria and the past evidence 
states that dental plaque is the primarily etiological factor for the progression of periodontal 
disease[21]. 
The rationale is that patients with periodontitis are chronically exposed to non symptomatic 
bacteriemias at increased levels, for longer duration, and with greater microbial diversity of 
infections, which increase with periodontal disease severity[47].  Some studies  also reported 
that elevated antibodies to selected periodontal pathogens titers were associated with increased 
atherosclerosis even among never-smokers[48-52]. 
A direct approach to assessing exposure to periodontal microbes is to measure bacteria 
quantitatively in periodontal and atherosclerotic plaque samples. 
Several studies have attempted to demonstrate the presence of periodontal bacteria or their 
components in human atherosclerotic lesions. A distinct pathogenic consortium of 
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Porphyromonas Gingivalis, Treponema Denticola and Tannerella forsythia (the red complex) is 
found in subgingival plaque in severe periodontitis and bacterial genomic 16S rDNA from 
numerous oral and periodontal species, including Porphyromonas Gingivalis, Treponema 
Denticola, T. Forsythia and F. Nucleatum have been detected in human clinical atherosclerotic 
plaque lesions[17, 53-55]. Chiu [56] performed a histologic analysis of human endoatherectomy 
carotid specimens and found P. Gingivalis and Streptococcus Sanguis in unstable plaques. 
Ishihara et al[57] detected Actinobacilus Actinomycetemcomitans, Bacteriodes Forythus, 
Treponema Denticola and Campylobacter Rectus in samples of coronary artery plaques by 
polymerase chain reaction. Furthermore, the presence of A. Actinomycetemcomitans, 
Fusobacterium nucleatum-periodonticum-simiae group, P. Gingivalis, Prevotella Intermedia, 
Prevotella nigrescens and T. Forsythia in atheromatous plaques from coronary arteries have 
been demonstrated by Gaetti-Jardim Jr et al[58] using PCR. 
Then in recent years, many researchers have focused their attention on the ability of periodontal 
pathogens to colonize in the atheromatous plaque in order to substantiate the potential role of 
the periodontal bacteria in the progression of atherosclerosis. Nevertheless, a clear correlation 
between the detection rates of periodontopathic bacterial DNA in atheroma and periodontal 
pockets has not been established. An indian study from Mahindra et al[21] revealed the 
presence of the red complex bacteria (P Gingivalis, T. Denticola, T Forsythia) in coronary 
atherosclerotic plaque in patients underwent CABG. Takahiro et al[59] detected DNA of 
periodontal bacteria in coronary thrombi in 22.2% of patients associated with myocardial 
infarction. But with current knowledge, we cannot answer the question of whether periodontal 
bacteria become attached to already existing atherosclerotic lesions or these bacteria promote 
the atherosclerosis and induce instability of plaque. 
1.2.2 MECHANISMS BY WHICH PERIODONTITIS MAY RELATE TO 
CARDIOVASCULAR DISEASE 
A number of reviews have been published that outline potential biological mechanisms linking 
infections and periodontal disease to cardiovascular disease[60-62]. 
1.2.2.1 DIRECT PATHWAYS 
Oral microbes and their byproducts can gain systemic access via the circulatory system. Gentle 
mastication can induce endotoxemia and this risk is elevated according to an increased severity 
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of periodontal disease[63], also dental procedures and toothbrushing can induce 
bacteriemias[46, 64]. It is this common and recurrent transient bacteremia that has been 
proposed to produce chronic insult to the vasculature and contribute to the injury and 
inflammation that initiates the development of atherosclerosis[25]. 
In gaining, systemic access, oral microbes have the potential to directly influence subclinical 
mediators of cardiovascular events such as hypercoagulability, atherosclerotic development or 
both. Animal studies demonstrated that intravenous inoculation with P Gingivalis accelerates 
atherosclerotic developement[65] and oral inoculation of P Gingivalis demonstrate accelerated 
early atherosclerosis with finding of bacterial DNA in the aortic tissue[18]. In vitro studies 
demonstrate the ability of Streptococcus Sanguis and P gingival to induce platelet aggregation 
and hypercoagulability[28, 62, 66]. 
1.2.2.2 INDIRECT PATHWAYS 
Atherosclerosis, as mentioned, has a strong inflammatory component, and epidemiological 
evidence suggests that increased levels of systemic inflammation are predictive of 
cardiovascular events[67]. People with periodontal disease have elevated levels of systemic 
inflammatory markers, such as C-Reactive Protein[68]. There are many potential triggers for this 
enhanced systemic inflammatory response, including transient bacteremias and local release of 
bacterial byproducts such as lipopolysaccharide[69].  
Another plausible mechanism is molecular mimicry, in which antibodies targeted toward 
bacterial species inadvertently cross-react with host cells[28]. Immune recognition of periodontal 
pathogens results in progressive inflammation consisting of an immune cell infiltrate, such as 
monocytes and B and T cells, and production of inflammatory mediators. As inflammation 
progresses to a more chronic state, the lesion becomes composed of a cellular infiltrate that is 
predominantly monocytic. Monocytes become activated macrophages, which further accelerate 
bone resorption through differentiation into osteoclasts and production of tissue-damaging 
proinflammatory cytokines[25]. Furthermore, additional proinflammatory mediators such as IL-8 
and IL-1β have been detected in the gingiva from patients with periodontal disease. 
Atherosclerosis begins with a dysfunctional endothelium, resulting in recruitment of a number of 
immune cells, such as macrophages and T cells, into the lesion. Inflammation within the lesion 
progresses when immune cells become activated by ligands present in the vasculature, 
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resulting in the production of a number of proinflammatory mediators that further propagate 
inflammation[25].   
Amongst the most extensively studied markers of inflammation, which have become 
increasingly associated with inflammatory diseases such as atherosclerosis, are the Toll-like 
receptors (TLRs)[70]. Receptors in the TLR family recognize specific, conserved pathogen-
associated molecular patterns (PAMPs) and, upon ligand recognition, TLRs orchestrate an 
inflammatory cascade. But it is also known that TLRs can also be engaged by endogenous 
ligands. Further, endogenous ligands, such as oxidized LDL, have been found to engage TLRs 
expressed on monocytes cells, resulting in lipid-laden foam cells that characterize the earliest 
stages of lesion development[71]. This finding, amongst others, gave rise to the notion that 
ligands of microbial origin may also contribute to the detrimental inflammatory reactions within 
atherosclerotic lesions. Due to the predominant role of TLRs in atherosclerosis progression, 
Slocum and colleagues[25] have investigated the association between TLRs and P. gingivalis-
mediated atherosclerosis and demonstrated that P. gingivalis-mediated TLR2 activation 
contributes to atherosclerosis progression. Activation of Toll-like receptor-2 (TLR2) abundantly 
expressed by endothelial cells of atherosclerotic plaques contributes to endothelial apoptosis 
and denudation. TLR2 ligands also include some components of gram-positive bacteria, 
indicating that some infectious factors may function to contribute to atherothrombosis via such 
mechanism. These data indicate that infectious agents may be at least partially implicated in 
both pathogenesis of atherosclerosis and manifestation of cardiovascular disease proving that 
involvement of microorganisms in the processes described above requires additional studies.  
Heat shock proteins can also have an important role. Infections with proatherogenic organisms 
may be important in individuals lacking additional risk factors as well as acting synergistically 
with established risk factors. In this process, Heat shock proteins may be a link between 
infections and the pathogenesis of atherosclerosis. Infectious agents may exert their role by 
producing their own Heat Shock Proteins and inducing host production which could be released 
into blood. The soluble form of Heat shock Proteins contact endothelial cells and immune cells 
where innate immune responses are initiated. Innate immune reactions to Heat Shock Proteins 
result in proinflammatory responses in the vessel wall. Together, infections via Heat shock 
Proteins contribute to the development of atherosclerosis. 
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1.3 STROKE AND CAROTID ATHEROSCLEROSIS  
Stroke, or cerebral infarction places a significant burden on to patients, their families, the 
healthcare system and aged-care services. Occlusive disease of the extra-cranial carotid artery 
is a leading cause of stroke. In 2009–2010 there were 35,345 hospitalisations with a principal 
diagnosis of stroke and 15,704 for transient ischaemic attack (TIA). Those rates increase 
substantially with age to be highest in the over 85 year category. The gender distribution was 
evenly spread with 52% of those hospitalisations for males. Forty-eight percent of 
hospitalizations were for ischaemic stroke, 29% for haemorrhagic stroke with the remaining 23% 
unspecified. Approximately 20–30% of ischaemic cerebral infarction result from atherosclerotic 
disease of either the intracranial or extracranial cerebral blood arteries. This may result from 
progressive stenosis causing an area of watershed ischaemia, or more commonly turbulence, 
plaque rupture and embolisation lodging in the terminal cerebral circulation. Around 30% of all 
cerebral infarctions come from a cardio-embolic source and that proportion may be higher in 
young people. Carotid artery stenosis or occlusion is thought to be associated with 11.5% of 
ischaemic stroke (3). The risk of stroke is thought to increase with the severity of stenosis, 
previous stroke or TIA, age, tobacco use and presence of diabetes. Strokes related to the 
carotid artery typically affect the brain in the territory of the anterior and middle cerebral arteries.  
With this introduction concerning the epidemiology it is clear that management of carotid 
bifurcation stenosis is a cornerstone of stroke prevention.  
Initial hopes that carotid endarterectomy could reverse the clinical course of stroke were proven 
false, and the role of surgical management of extracranial carotid and vertebral obstructions was 
defined by one of the earliest efforts at a multicentered randomized clinical trial, The Joint Study 
on The Extracranial Circulation in 1968[72]. The results of this decade-long study, involving 5000 
patients, established the role of carotid endarterectomy in the treatment of minor stroke, 
transient ischemic attack (TIA), and amaurosis fugax, confirmed that surgery had a limited role 
in the treatment of established stroke, and established the limited role of vertebral reconstruction 
in the treatment of cerebral insufficiency. Over the ensuing decades, surgical results of carotid 
endarterectomy improved, asymptomatic carotid stenosis was increasingly identified by 
noninvasive studies, and carotid endarterectomy assumed a primarily prophylactic role as 
prevention of major stroke in asymptomatic patients or those with evidence of transient cerebral 
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or ocular ischemia. Large randomized trials have established the role and efficacy of carotid 
endarterectomy (CEA) in stroke prevention[73].  
The committee[73] recommends carotid endarterectomy as the first-line treatment for most 
symptomatic patients with stenosis of 50% to 99% and asymptomatic patients with stenosis of 
60% to 99%. The perioperative risk of stroke and death in asymptomatic patients must be <3% 
to ensure benefit for the patient.  
1.3.1 ENDARTERECTOMY 
1.3.1.1 HISTORY 
Endarterectomy, first performed by J. Cid dos Santos in 1946, was originally designed for simple 
removal of thrombi. Dos Santos , later, due to bad outcomes, decided to do this operation with 
the patient under the cover of heparin and stated: "I really had performed a different operation 
from the one I originally intended to do; and I could conclude that, under heparin action, blood 
could flow against muscle without giving place to thrombosis” 
This new procedure, later called thromboendarterectomy, represented a wholly new concept in 
arterial surgery. It appeared as a revolutionary idea because it seemed to negate the prevailing 
concept, according to which an injured intima leads inevitably to vascular thrombosis. Indeed, in 
thromboendarterectomy both the thrombus and the endartery (intima and part of the inner 
media) are excised. 
The accidental finding that arterial thrombosis does not necessarily occur after removal of the 
intimal lining and a portion of the media is a typical example of “serendipity”. 
Dos Santos's pioneering efforts were soon confirmed and expanded. Originally dos Santos 
named this operation "arterial disobstruction” or "disobliteration." Later Bazy and Reboul coined 
the term endarterectomy, but Leriche preferred the more comprehensive term 
thromboendarterectomy. These two terms, often used interchangeably, are designed to indicate 
removal not only of the intima and thrombus but also of the media. 
A combination of systemic and local heparinization offers the best method for preventing 
thrombosis during these usually long procedures. Postoperative heparinization has been 
abandoned because the possible troublesome complications outweigh its effectiveness in 
preventing thrombosis at this stage. 
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1.3.1.2 PATIENT CHARACTERISTICS  
The ideal candidate for carotid endarterectomy, would be a normotensive individual without 
cardiac symptoms, younger than 70 years, preferably male, who had suffered one or more focal 
cerebral hemispheric transient ischemic neurologic episodes within the preceding 120 days and 
was found to have 70% to 99% stenosis of the appropriate ipsilateral internal carotid artery at its 
origin, in the absence of other intracranial or extra cranial arterial lesions on imaging. 
The cerebral CT scan ideally should show that the involved cerebral hemisphere received its 
blood supply via the circle of Willis from the contralateral unaffected internal carotid artery and 
that the posterior communicating arteries were patent. Scans should not show any sign of 
cerebral infarction. The patient should have tolerated daily aspirin ingestion, and would be 
expected to continue to tolerate it for the rest of his life. 
Unfortunately, many strokes occur without warning symptoms, and once they have occurred it is 
usually impossible to reverse the ischemia completely and bring about full functional and 
anatomic recovery. That stroke can be prevented in symptomatic patients with severe carotid 
stenoses has been clearly demonstrated[74-76]. The variations in presentation, which may 
markedly influence surgical risk and long-term outcome, are almost innumerable; 
The factors that influence immediate surgical outcome can be classified as: 
1) nature and extent of arterial pathology 
2) clinical condition of the Patient  
3) cerebral pathology  
4) experience of the surgeon 
The factors that influence late outcome and disease 
modification can be classified as:  
1) specific therapy  
2) modification of risk factors 
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1.3.1.3 NATURE AND EXTENT OF CAROTID PATHOLOGY 
1.3.1.3.1 The Carotid Plaque 
The carotid bifurcation plaque, responsible for approximately 70% of all ischemic strokes, is 
found in various stages of evolution in both symptomatic and asymptomatic patients[77]. 
As mentioned, neurologic symptoms and stroke correlate not only with the degree of stenosis, 
which may impede flow, but also with the nature of the plaque. As the carotid plaque is the result 
of a sometimes rapidly evolving process and strokes frequently occur without warning, one must 
conclude that a minimum of 50% to 70% diameter reduction (75% cross-sectional area) in the 
presence of symptoms characteristic of transient cerebral ischemic attacks, with no other 
detectable source of microemboli, constitutes an indication for operative intervention if no 
contraindications exist. 
1.3.1.3.2 Unilateral Carotid Involvement 
Unilateral and isolated carotid involvement 
presents the ideal pathologic lesion for surgical 
intervention because, unless there are major 
gaps in the circle of Willis, compensatory flow 
can occur during carotid clamping needed to 
perform endarterectomy. On occasion, 
however, even unilateral involvement may be 
associated with carotid clamping intolerance. 
1.3.1.3.3 Bilateral Carotid Involvement 
When bilateral markedly stenotic plaques are 
encountered, an order of precedence must be 
decided based on cerebral angio-imaging and 
symptoms. Unless one plaque is outstanding 
because of symptoms threatening early stroke, 
the concept of carotid predominance has been 
a useful guide. The carotid artery that supplies 
t h e c o n t r a l a t e r a l h e m i s p h e r e ( t h e 
"predominant" or "major" artery) is susceptible to clamping intolerance. Therefore the non 
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predominant or "minor" artery is operated on first, followed by operation one or more weeks later 
on the predominant artery, 
1.2.1.3.4 Stenosis and Occlusion 
Stenosis opposite an occlusion requiring operation offers the greatest risks of clamp intolerance 
and creates the greatest risk of perioperative stroke. Operations in this cohort of patients may 
incur 10% to 15% operative risk requiring extraordinary measures beyond merely employing 
shunts routinely. It is essential, as well, to avoid hemodynamic instability, which, even in the 
presence of a patent intraluminal shunt, may predispose to stroke. Nevertheless, a number of 
strategies have been used to ensure safety of operations on stenotic carotid arteries opposite 
occlusions, ranging from operating on conscious patients with selective shunting to the routine 
use of shunts under general anesthesia. 
1.3.2 CLINICAL CONDITION OF THE PATIENT 
1.3.2.1 Neurologic Condition 
Stenotic arterial disease of the cerebral circulation, which lends itself to carotid endarterectomy, 
manifests in a variety of ways. Symptoms may occur unexpectedly and suddenly from massive 
cerebral infarction causing catastrophic nonremediable stroke, or may be evanescent and 
sometimes difficult to recognize 
The severity of the pathologic process in the arteries is not necessarily reflected in the severity 
of symptoms or in the degree and extent of existing cerebral damage. Frank infarcts may 
present with minimal or no symptoms as may multiple occlusive or embolizing arterial lesions. 
The neurologic status therefore becomes a vital issue in selection of patients for operation, not 
only to attempt to recognize those who, with minimal or no symptoms, are at risk of suffering 
catastrophic stroke, but also to estimate operative risks as they relate to clinical status. Of equal 
importance is whether clinical improvement can be expected to occur in the presence of 
neurologic impairment. 
1.3.2.2 Non-neurologic Factors 
1.3.2.2.1 Age 
Although age is heavily weighted in evaluating patients for operative procedures, it has become 
apparent that age itself need not be considered a contraindication to carotid endarterectomy. 
Therefore, estimation of surgical risks in octogenarians and older individuals should be with 
reference to specific risk factors other than age. 
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1.3.2.2.2 Coronary Artery Disease 
The concurrence of coronary and carotid artery disease has been frequently convincingly 
documented as has the impact of one upon the other in the operating room. Even in the 
absence of clinical symptoms, 14% of patients considered for carotid endarterectomy had 
angiographic evidence of severe operable coronary artery disease. 
Patients with severe coronary artery disease manifested by unstable angina, recent acute 
myocardial infarction, low left ventricular ejection fractions, markedly positive stress tests, left 
main coronary stenosis, or "triple vessel disease" require particular consideration for how to 
manage symptomatic or severely stenotic carotid disease. Strategies range from performing 
both operations at the same operative session, with neurologic complication rates that range 
from low to as high as 9.5%, to attempting to "uncouple" the procedures by operating on the 
more threatening procedure first. 
1.3.2.3 Techniques 
A successfully performed operation requires strict adherence to a set of principles aimed at 
avoiding a number of well-defined operative complications, any one of which can destroy the 
effectiveness of the procedure. The principal complications to be avoided are  
1) cerebral clamping ischemia 
2) cerebral embolization 
3) operative site thrombosis 
1.3.2.4 Cerebral Clamping ischemia 
The design of the intracerebral circulation, with its circle of Willis, was seemingly to ensure 
adequate total cerebral blood flow from any one of the extracranial cervical arteries. Its 
execution, however, has resulted in various gaps in the circle through defects or absences of 
various communicating arteries that complete the circle, as occurs in 30% of humans even 
without arterial occlusive disease[1]. 
When cerebral ischemia occurs, signs may appear within seconds of application of clamps (8 to 
30 seconds under local anesthesia), and recovery is equally prompt on their removal or on 
restoration of flow through temporary inlying shunts. The longest duration of total ischemia 
compatible with complete recovery in humans is not certainly known but may be as short as 2 to 
5 minutes, in any event much too short to permit the completion of a well-performed carotid 
endarterectomy. The problem is complicated by the fact that unilateral carotid endarterectomy 
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rarely results in total ischemia because some circulation is usually maintained through 
collaterals, and only when regional flow is decreased 64% signs of cerebral ischemia appear. 
Well-functioning intralumenal shunts are the most reliable devices that correct clamping cerebral 
ischemia. 
1.3.2.5 Operative Site Thrombosis 
Operative site thrombosis may occur in the absence of symptoms, may cause only transient 
ischemic neurologic deficits, or may precipitate catastrophic stroke and death. Mechanisms 
leading to thrombosis usually result from technical errors such as incomplete removal of plaque, 
from edges or intimal flaps in the internal carotid artery at the distal termination of the 
endarterectomy, from uncorrected kinks of the internal carotid artery that become accentuated 
following endarterectomy, from stenosis produced by primary arteriotomy closure, from posterior 
wall buckling caused by too short a roof patch for the length of the arteriotomy, from stasis clot 
forming in the isolated endarterectomized segment during arteriotomy closure, due to 
inadequate heparinization, insufficient flushing, or from insufficient irrigation of the 
endarterectomy site just prior to final closure of the arteriotomy. 
Reexploration of the operative site is usually indicated upon detection of an early neurologic 
deficit. Delay beyond 1 or 2 hours may result in permanent neurologic damage.  
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2. STUDY 
2.1 MATHERIALS AND METHODS 
Is a prospective monocentric study and the aim is to ascertain the presence of periodontal 
bacterial DNA in carotid atheromatous plaque in dentate patients and to assess the concomitant 
presence of the same microbiome, if any, in both periodontal pockets and carotid atheroma in 
each dentate patient. 
2.1.1 PATIENTS SELECTION 
Six patients scheduled to undergo carotid endarterectomy at Centro Cardiologico Monzino were 
recruited for this study and they were cooperative and readily accepted for the study. The 
patients were identified as candidate for carotid endarterectomy according to the standard 
medical practice and guidelines (all patients were diagnosed with atherosclerotic disease 
involving the internal carotid artery documented by color duplex ultrasound and contrast CT 
scan with ≥70 % stenosis) . 
Inclusion criteria were age > 18 years old, surgical indication (based on international guidelines), 
signature of informed consent. 
Exclusion criteria includes antibiotic intake or an history of periodontal treatment carried out in 
the previous six months, edentulous subject, chronic inflammatory pathologies that requires 
steroid or immunosuppressive therapy. 
The informed consent was obtained from the subjects. The Ethics Committee of the Centro 
Cardiologico Monzino/Instituto Europeo di Oncologia approved the protocol of this study. 
Medical and dental history of each patient was obtained by an interview. The periodontal 
examination was done using periodontal chart from ZMK Bern University. 
 
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2.1.2 SUBGINGIVAL PLAQUE COLLECTION 
A complete periodontal examination (pocket depth, clinical attachment level, plaque index, 
bleeding on probing), including radiographic orthopanoramic, was done by a single specialist 
(FC). The subgingival plaque samples were taken one or two days before patients underwent 
carotid endarterectomy. The deepest periodontal sites with periodontal depth ?5mm were 
selected for microbial sampling. The teeth were gently dried with a sterile cotton swab. after 
removal of the supra gingival plaque, the sub gingival plaque samples were obtained with the 
help of a curette and were pooled for analysis. 
2.1.3 SURGICAL INTERVENTION 
Under local or general anesthesia a cervical incision is made 
parallel and anterior to the sternocleidomastoid and centered 
over the carotid bifurcation.  
This incision can be extended proximally to the sternal notch for 
more proximal lesions of the common carotid artery (CCA) and 
distally to the mastoid process for higher exposure. Its upper 
end was angled posterior to the earlobe to avoid the parotid gland and the greater auricular 
nerve. The incision is carried down through the platysma, and the sternocleidomastoid is 
retracted laterally with self-retaining retractors. The internal jugular vein is visualized, and the 
carotid sheath is opened along the anterior border of the vein. The internal jugular vein is 
retracted laterally. Dissection is continued anterior to 
the CCA to keep from injuring the vagus nerve. The 
vagus nerve usually lies in a posterior lateral position 
within the carotid sheath but occasionally may spiral 
anteriorly, particularly in the lower end of the incision. 
Attention should be paid to cranial nerves IX 
(glossopharyngeal nerve), X (vagus nerve), XI 
(accessory nerve), and XII (hypoglossal nerve), as 
well as the marginal mandibular branch of VII (facial 
nerve) and the rare nonrecurrent laryngeal nerve that 
comes directly off the vagus to innervate the vocal 
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cords. This nerve can cross anterior to the carotid artery and can be mistaken for a part of the 
ansa cervicalis; if it is inadvertently divided, cord paralysis results. A nonrecurrent laryngeal 
nerve is most often noted on the right side of the neck. 
The CCA is mobilized proximal to the carotid lesion. Dissection is continued upward to isolate 
the external carotid artery (ECA). The internal carotid artery (ICA) is mobilized up to a point 
where the vessel is completely normal. Because the hypoglossal nerve may be injured by 
retraction, every effort was made to minimize traction on this nerve. Careful attention should 
also be given to the superior laryngeal nerve, which is usually located medial to the ICA. This 
nerve divides into external and internal branches that pass posterior to the superior thyroid 
artery and may be harmed while the surgeon is attempting to control either this vessel or the 
ICA. The glossopharyngeal nerve crosses the ICA near the base of the skull and is best 
protected by maintaining dissection close to the anterior surface of the ICA. 
Control of the CCA is obtained proximal to the level of disease by surrounding the vessel with an 
umbilical tape. Once proximal control is obtained, dissection is continued distally around the 
ECA and its first branch, the superior thyroid artery. Subsequently, control is obtained distally at 
the ICA. 
Throughout the dissection, it is important to minimize manipulation of the carotid artery so as to 
reduce the risk of embolization. Dissection must be carried out with extreme care taken to avoid 
injuring surrounding nerves, most notably the vagus and hypoglossal nerves. The ansa 
cervicalis, a branch of the hypoglossal nerve, may have to be divided to facilitate the dissection; 
this is acceptable. 
Heparin (5000-7000 U) is administered intravenously. The ICA, the CCA, and the ECA are 
occluded, in that order. An arteriotomy is made, starting anteriorly on the CCA proximal to the 
lesion and extending cephalad through the plaque opposite the flow divider, then continued into 
the ICA with Potts scissors. Distal to the plaque, the arteriotomy is extended until it reaches a 
point where the ICA is relatively normal. 
When neurologic changes are noted during monitoring, a shunt is placed by inserting the distal 
end of the shunt into the normal ICA distal to the lesion. Back-bleeding the shunt clears any air 
or debris, and the proximal end of the shunt is then placed well into the CCA, proximal to the 
plaque. The endarterectomy proper is begun with a Penfield elevator. The optimal 
endarterectomy plane is that between the inner and outer medial layers. The cleavage plane is 
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the key to the performance of an endarterectomy. The proximal endpoint is obtained by sharply 
dividing the plaque in the CCA. The plaque can be elevated under full vision while the 
endarterectomy is continued into the carotid bulb. Carotid plaque that extends a short distance 
into the ICA may be teased medially toward the origin of the ECA to achieve an adequate 
endpoint. The plaque can also be divided in the bulb so that the ICA and ECA endarterectomies 
can be conducted independently. 
Once the plaque is divided, the device (clamp or loop) used to control the ECA is loosened, and 
an eversion endarterectomy is performed. In the ICA, the divided plaque is feathered so that a 
smooth taper is achieved in the transition to the normal distal intima. If a smooth distal taper is 
not achieved, placement of interrupted 7-0 monofilament tacking sutures may be necessary to 
secure the endpoint. 
After completion of the endarterectomy, all residual debris and medial fibers are excised 
because of their potential contribution to embolization or hyperplastic restenosis. The 
endarterectomy surface is irrigated with heparinized saline solution to facilitate visualization and 
removal of all debris. Before 
the clamps are removed, 
flushing must be done from 
each direction. The ICA is 
unclamped last. As a rule, a 
c o n v e n t i o n a l c a r o t i d 
endarterectomy is closed with 
a dacron patch or direct 
suture. Before closure is completed, heparinized saline solution is used to flush the ECA, the 
ICA, and the CCA. The shunt, if present, is removed, and the final few stitches are placed. Flow 
is then reestablished to the ECA and subsequently to the ICA.  
Complete hemostasis is obtained. A closed suction drain is placed. The wounds are closed with 
routine technique. 
2.1.3.1 CONSCIOUS PATIENT 
The technique used for carotid endarterectomy in the conscious patient: with minimal 
premedication only, insufficient to cause drowsiness and inability to respond promptly to verbal 
commands, the patient is positioned on the operating table supine, the head turned away from 
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the operative side. A compressible squeaker toy is strapped in the palm of the hand opposite the 
side of operation. Cervical block anesthesia is administered injecting 0.5% marcaine. 
2.1.4 COLLECTION OF ATHEROSCLEROTIC PLAQUE 
After described endarterectomy the plaque was collected and placed in a vial with sterile saline 
solution, free of previous contaminating DNA. After surgery, all obtained plaque samples did not 
get in contact with any potential contaminants. 
2.1.5 MICROBIOME DNA EXTRACTION 
To purify bacterial DNA we implemented the PureLink Microbiome DNA purification kit 
(Invitrogen), following the manufacturer’s instruction. The protocol was used both for DNA 
extraction from dental plaques as well as carotid plaques. Briefly, we added 800 uL of lysis 
buffer and transferred the whole content to the bead tube. Then, we added 100 uL of lysis 
enhancer, vortexed the suspension, and incubated for 10 minutes at 65°C. Subsequently, we 
homogenize by bead beating for 10 minutes on a vortex at maximum speed. At the end, we 
centrifuge the samples at 14’000 x g for 2 minutes, recovering 500 uL of supernatant. At this 
point, we added 900 uL of binding buffer and loaded onto a spin column-tube capable to capture 
the DNA. We washed the column with 500 uL of wash buffer, to remove all possible 
contaminants. We then proceeded with the elution step, adding 100 uL of elution buffer. We 
repeated this step twice to increase the DNA recovery. Finally, we quantify the total amount of 
DNA by the classical absorbance method. We stored the samples at -80°C until the analyses. 
As expected the amount of DNA recovered from all the plaques was between 15 to 85 ng/µL. As 
shown in fig A the total amount of DNA in dental plaques was lower than carotid plaques. All the 
DNA extracted from carotid plaques was of bacterial origin, while DNA extracted from carotid 
plaques was of human and bacterial origin. Real Time PCR analysis evaluating 16s in carotid 
plaques, revealed that 5 samples out of 6 had detectable amount of bacterial DNA (fig B). Plot C 
shows the relative percentage of bacterial DNA in human carotid plaques, ranging from 9 to 
25%. 
 27
2.1.6 NEXT GENERATION SEQUENCING 
The extracted DNA (from host and bacterial, not purified) was send to Eurofins Genomics, 
Ebersberg, Germany for 16S Microbiome profiling to identify the microbial community in our 
samples sequencing V1-V3 region. 
The amount of bacterial DNA was very low in carotid plaques, Eurofins lab tried unsuccessfully 
to generate amplicons. Sequencing samples without an amplicon will result in no or very few 
reads that will give no reliable results. In addition samples without an amplicon will diluite the 
pool which will result in a weak coverage across all samples so we decided to sequencing only 
dental plaques. 
figure A
figure B figure C
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The sorting of sequencing reads according to barcodes and primer sequences has been 
performed with in-house scripts. Only read pairs where the expected 5’ barcode and forward 
primer as well as the expected 3’ barcode and reverse primer were found have been kept for 
further analysis. For the identification of barcode and primer sequences no mismatches were 
allowed. The “Debarcoding results” table provides various statistics describing the sorted reads.  
2.1.7 MICROBIOME PROFILING 
Prior to the microbiome analysis, raw reads were demultiplexed/debarcoded based on the 
unique forward and reverse sequencing indices and/or inline-barcode sequences. To preserve 
only high-quality reads, all reads with sequencing errors the barcode or primer sequences or 
with ambiguous bases ("N") were removed. Indices/barcodes as well as primer sequences were 
clipped from the reads. The remaining set of high-quality reads was processed using minimum 
entropy decomposition[78]. Minimum Entropy Decomposition (MED) provides a computationally 
efficient means to partition marker gene datasets into OTUs (Operational Taxonomic Units). 
Each OTU represents a distinct cluster with significant sequence divergence to any other 
cluster. By employing Shannon entropy, MED uses only the information-rich nucleotide positions 
across reads and iteratively partitions large datasets while omitting stochastic variation. The 
MED procedure outperformes classical, identity based clustering algorithms. Sequences can be 
partitioned based on relevant single nucleotide differences without being susceptible to random 
Debarcoding Results
Sample #Read Pairs Yield (Kbp) %Q30 Mean Q
F01 PD 146,007 82,055 80,47 32,43
F02 PD 158,399 89,020 80,45 32,45
F03 PD 166,669 93,667 80,57 32,50
F04 PD 165,524 93,024 79,82 32,26
F05 PD 110,133 61,894 79,68 32,21
F06 PD 135,417 76,104 80,43 32,42
F01 PC // // // //
F02 PC // // // //
F03 PC // // // //
F04 PC // // // //
F05 PC // // // //
F06 PC // // // //
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sequencing errors. This allows a decomposition of sequence data sets with a single nucleotide 
resultion. Furthermore, the MED procedure identifies and filters random "noise" in the dataset. 
This includes singletons and putative chimeric sequences.  
To assign taxonomic information to each OTU, BLAST alignments of cluster representative 
sequences to the NCBI sequence database were performed. A most specific taxonomic 
assignment for each OTU was then transferred from the set of best-matching reference 
sequences. Hereby, a sequence identity of 80% across at least 80% of the representative 
sequence was a minimal requirement for considering reference sequences.  
Further processing of OTUs and taxonomic assignments was performed using the QIIME 
software package (version 1.8.0, http://qiime.org/). Abundances of bacteria and archaea 
taxonomic units were normalized using lineage-specific copy numbers of the relevant marker 
genes to improve estimates[79]. The amount of bacterial DNA is very low for half of  samples 
send to Eurofins (carotid plaque samples) and no amplicon could be generated and sequencing 
samples without an amplicon will result in no or very few reads that will give no reliable results. 
2.1.9 STATISTICS 
This section summarizes the results of read preprocessing, OTU picking, and taxonomic 
assignment.  
Summarized Statistics
Total number of input sequences 882,149 100%
Remaining sequences after preprocessing and quality filtering 882,149 100%
Total number of sequences assigned to OTUs 735,440 83,4%
Total number of sequences assigned to taxa 709,515 80,4%
Copy-number corrected total count 273,612 N/A
Total number of OTUs 3,027 100%
Number of OTUs assigned to taxa 2,915 96,3%
Sequences per sample assigned to OTUs Min 90,525
Max 142,101
Median 126,542
Mean 122,573
Std. Dev. 17,342
 30
The number of OTUs correlates with the diversity of the data set. Sequences that were 
considered as noise by the OTU picking algorithm were not assigned to an OTU. This includes 
singletons and putative chimeric sequences. The fraction of OTUs that could be assigned to 
taxa indicates how well the microbiome is represented in the used reference database. A copy-
number correction was performed for bacterial species only, see Angly FE et al[79]. To do so, 
the number of reads assigned to a species was divided by the known or assumed copy-number 
of marker genes/regions. The resulting corrected total count may be significantly lower than the 
(raw) total number of assigned reads. After preprocessing, sequences were clipped to 270 bp 
length to remove low quality bases from the 3’ end and to ensure that all sequences have the 
same length. The latter is crucial for the MED analysis.  
2.2 RESULTS 
We enrolled six patients with a a mean age of 72+5.8 years, with a prevalence of male gender 
(67%), an half of obese patient with a mean BMI of 29.4. We don’t enrolled smokers but we had 
67% of previous smoker. About 67% of patients had concomitant coronary artery disease. 
Population data in following table. 
Per Sample Statistics
1) 2) 3) 4) 5) 6)
F01 PD 146,007 146,007 120,831 115,807 42,155 280
F02 PD 158,399 158,399 132,253 126,239 47,659 280
F03 PD 166,669 166,669 142,101 140,060 54,263 280
F04 PD 165,524 165,524 136,882 131,323 51,583 280
F05 PD 110,113 110,113 90,526 88,084 33,162 280
F06 PD 135,417 135,417 112,848 108,002 44,790 280
TOTAL 882,129 882,129 735,441 709,515 273,612 280
1) Input sequences. 2) Sequences after preprocessing. 3) Sequences assigned to OTUs. 4) Sequences 
assigned to taxa. 5) Count after lineage-specific copy-number correction. 6) Median sequence length 
after preprocessing and before clipping. This table can be found as file in the results directory. Please 
see the according section for details about result files. 
Population characteristics
Age 72,2+5,8 CAD 67%
Male 67% previous CABG 17%
BMI 29,4+2,4 previous PCI 33%
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From periodontal chart we extrapolated some data: we have a mean probing depth of 3.1mm, a 
mean attachment level of -3.7mm, a mean plaque of 74% and a mean of bleeding on probing 
about 38%. 
Periodontal chart results showed a moderate periodontitis with gingival inflammation. 
About 50% of the surgical procedure was done under local anestesia, only in one patient was 
necessary to use a patch to close the carotid artery and in another patient we performed 
concomitant surgical myocardial revascularization. We had no death and no major morbidity. 
arterial hypertension 83% previous AMI 17%
dislipidemia 100% EF 61+2,8
Diabete 33% prepor statine 83%
previous smoking 67% BNP 103,4+106,2
Obesity 50% cholesterol mg/dL 158+27,3
COPD 17% triglycerides mg/dL 100,8+33,8
Creatinine mg/dL 1,2+0,67
 
Mean probing depth 
(mm)
0
0,95
1,9
2,85
3,8
F01 F02 F03 F04 F05 F06 Mean
 
Bleeding on probing (%)
0
15
30
45
60
F01 F02 F03 F04 F05 F06 Mean 
Plaque (%)
0
22,5
45
67,5
90
F01 F02 F03 F04 F05 F06 Mean
 
Mean attachment level 
(mm)
-6
-4,5
-3
-1,5
0
F01 F02 F03 F04 F05 F06 Mean
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The DNA  of at least one of the probed bacteria was detected in each subgingival samples. In 
carotid plaques not enough bacterial DNA was found to proceed with sequencing.  
2.2.1 TAXONOMIC COMPOSITION OF ORAL  PLAQUE SAMPLES 
The following table provides an overview of the identified taxonomic units in each sample. Next 
to each sample name, the total number of reads of this sample that were assigned to OTUs is 
given. The most specific taxonomic units are listed with their taxonomy level and fraction 
(k...kingdom, p...phylum, c...class, o...order, f...family, g...genus, s...species). The most specific 
taxonomic unit is the lowest common taxonomic unit of the listed species. These species came 
up as best hits of the OTUs representative sequences during the database comparison.  
All taxonomic units with less than 0.1% of reads are collapsed in the category "Other". If the 
representative sequence of an OTU had no significant database match, no taxonomic unit could 
be assigned. The total number of reads of these unassigned OTUs is stated as category 
"Unassigned". Depending on the type of analysis, some taxonomic units might be removed as 
they to not match the expected clade, e.g. eukaryotes in a bacterial microbiome analysis. The 
number of removed reads is stated as category "Filtered". If this category is not listed, no 
filtering was performed. Copy-number correction could be performed for bacterial species only. 
To do so, the assigned read count was divided by the known or assumed copy-number of 
marker genes/regions. If the listed normalized fraction and raw fraction are identical, either no 
copy-number correction factor was available in the database or the factor is exactly one. Copy-
number information is only available for bacterial species, see Angly FE et al. (2014).  
The following tables show the oral microbiome analysis of each patient containing a summarized 
list of identified taxonomic unit for each sample. The columns list all taxonomic unit with at least 
0,1% of reads assigned to them. All taxonomic unit with less than 0,1% of reads are collapsed in 
Intraoperative characteristics
General Anesthesia 50%
Local anesthesia 50%
Right TEA 33%
Left TEA 67%
Patch 17%
concomitant CABG 17%
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the category “other”. If the representative sequence of an OTU had no significant database 
match, no taxonomic unit could be assigned. The total number of reads of these unassigned 
OTUs is stated as category “unassigned”. Depending on the type of analysis some taxonomic 
units might be removed as they to not match the expected clade, e.g. eukaryotes in bacterial 
microbiome analysis. The number of removed reads is stated as category “filtered”. 
LEGEND: K=Kingdom, P=Phylum, C=Class, O=Order, F=Family, G=Genus, S=Species 
Patient F01 Patient F02
Taxonomic 
Level Taxonomic Unit Fraction Uncorrected
Taxonomic 
Level Taxonomic Unit Fraction Uncorrected
s Porphyromonas endodontalis 10,4% 3,8% s Campylobacter showae 4,9% 2,4%
s Fusobacterium nucleatum 7,7% 13,4% s Lautropia mirabilis 4,1% 1,5%
g Treponema 6,3% 3,9% s Actinomyces naeslundii 3,9% 2,0%
s Alloprevotella tannerae 5,9% 6,2% s Porphyromonas endodontalis 3,2% 1,2%
s Campylobacter rectus 5,2% 1,9% g Dysgonomonas 3,1% 1,2%
g Fusobacterium 3,4% 5,9% s Prevotella intermedia 3,0% 2,8%
s Prevotella sp. oral taxon 303 3,0% 3,0% s Aggregatibacter segnis 3,0% 3,5%
s Fusobacterium sp. oral taxon 203
2,8% 4,9% g Prevotella 2,9% 3,0%
s Prevotella oris 2,8% 2,7% g Streptococcus 2,8% 5,1%
s Bosea sp. R-38307 2,7% 1,5% s Capnocytophaga sp. oral taxon 329
2,7% 1,9%
s Parvimonas micra 2,3% 5,5% s Peptostreptococcus stomatis 2,7% 1,0%
s Tannerella sp. oral taxon BU063 2,1% 1,5% s Fusobacterium hwasookii 2,2% 4,0%
s Prevotella intermedia 2,0% 1,8% s Veillonella parvula 2,1% 5,3%
g Prevotella 1,9% 1,9% g Actinomyces 2,1% 1,0%
s Treponema socranskii 1,9% 1,2% s Prevotella sp. oral taxon 317 2,0% 2,0%
s Corynebacterium matruchotii 1,6% 1,2% s Corynebacterium sp. oral taxon B00 1,6% 1,3%
s Lachnoanaerobaculum saburreum 1,6% 1,5% s Capnocytophaga granulosa 1,6% 1,1%
s Eubacterium brachy 1,5% 2,7% g Fusobacterium 1,5% 2,6%
s Johnsonella ignava 1,3% 0,5% s Corynebacterium matruchotii 1,5% 1,2%
s Rickettsia raoultii 1,1% 0,4% g Corynebacterium 1,4% 1,1%
s Prevotella sp. oral taxon 317 1,1% 1,0% s Leptotrichia buccalis 1,4% 2,4%
s Campylobacter gracilis 1,0% 0,4% s Propionibacterium propionicum 1,4% 1,1%
s Capnocytophaga sp. oral taxon 329 0,9% 0,6% s Abiotrophia defectiva 1,3% 1,5%
s Fretibacterium fastidiosum 0,9% 1,1% s Leptotrichia sp. oral taxon 225 1,3% 2,3%
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s Fusobacterium sp. oral taxon A11 0,8% 1,4% s Neisseria sicca 1,2% 1,7%
s Fusobacterium sp. oral taxon C10 0,8% 1,3% s Leptotrichia sp. oral taxon 392 1,2% 2,1%
s Actinomyces meyeri 0,8% 0,4% s Treponema socranskii 1,2% 0,7%
s Porphyromonas sp. oral taxon 279 0,7% 0,6% g Porphyromonas 1,1% 0,9%
s Fretibacterium sp. feline oral taxon 223 0,7% 0,9% s
Capnocytophaga sp. oral 
taxon B29 1,1% 0,7%
g Streptococcus 0,7% 1,2% s Catonella morbi 1,0% 0,7%
s Catonella morbi 0,7% 0,5% s Streptococcus sp. oral taxon C54 1,0% 1,8%
s Leptotrichia sp. oral taxon 462 0,6% 1,1% s Neisseria elongata 0,9% 1,3%
s Eikenella corrodens 0,6% 0,2% s Actinomyces sp. oral taxon 178
0,9% 0,4%
g Corynebacterium 0,6% 0,4% s Actinomyces dentalis 0,8% 0,4%
s Leptotrichia sp. oral taxon B57 0,6% 1,0% s Fusobacterium nucleatum 0,8% 1,4%
s Atopobium rimae 0,6% 0,3% o Burkholderiales 0,8% 1,0%
s Campylobacter showae 0,6% 0,3% s Porphyromonas gingivalis 0,7% 0,6%
s Eubacterium sp. oral strain A35MT
0,5% 0,9% s Bosea sp. R-38307 0,7% 0,4%
f Lachnospiraceae 0,5% 0,5% s Eikenella corrodens 0,7% 0,3%
s Actinomyces sp. oral taxon 525 0,5% 0,2% s Capnocytophaga sputigena 0,7% 0,5%
g Olsenella 0,4% 0,2% s Campylobacter gracilis 0,7% 0,3%
s Tannerella sp. oral taxon 808 0,4% 0,3% s Prevotella melaninogenica 0,7% 0,5%
s Peptostreptococcus stomatis 0,4% 0,2% s Prevotella oris 0,7% 0,7%
s Leptotrichia hofstadii 0,4% 0,7% s Lachnoanaerobaculum cf. saburreum oral strain C27KA 0,7% 0,7%
s Treponema amylovorum 0,4% 0,2% s Streptococcus sanguinis 0,7% 1,2%
s Capnocytophaga granulosa 0,4% 0,3% s Atopobium rimae 0,7% 0,3%
g Porphyromonas 0,4% 0,3% s Treponema sp. oral taxon 230 0,6% 0,4%
s Mogibacterium timidum 0,4% 0,6% s Actinomyces sp. oral taxon 449 0,6% 0,3%
s Capnocytophaga genosp. AHN8471 0,4% 0,2% g Capnocytophaga 0,6% 0,4%
s Propionibacterium propionicum 0,3% 0,3% g Selenomonas 0,6% 1,4%
s Treponema sp. oral taxon 270 0,3% 0,2% g Leptotrichia 0,6% 1,0%
g Dysgonomonas 0,3% 0,1% s Capnocytophaga gingivalis 0,6% 0,4%
s Treponema maltophilum 0,3% 0,2% s Peptostreptococcus sp. oral taxon 113
0,6% 0,2%
g Aggregatibacter 0,3% 0,6% s Porphyromonas sp. oral taxon 278
0,6% 0,5%
s Lachnoclostridium jejuense 0,3% 0,3% s Leptotrichia sp. oral taxon 498 0,6% 1,0%
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s Oribacterium sp. oral taxon 372 0,3% 0,3% f Lachnospiraceae 0,6% 0,6%
s Leptotrichia buccalis 0,3% 0,5% s Bergeyella sp. oral taxon 322 0,5% 0,6%
s Capnocytophaga gingivalis 0,3% 0,2% s Actinomyces israelii 0,5% 0,3%
s Selenomonas sputigena 0,3% 0,7% s Alloprevotella sp. oral taxon 473 0,5% 0,6%
c Alphaproteobacteria 0,3% 0,2% g Olsenella 0,5% 0,2%
s Prevotella sp. oral taxon 781 0,3% 0,3% s Rickettsia raoultii 0,4% 0,2%
s Aggregatibacter sp. oral taxon 458 0,3% 0,5% s Porphyromonas catoniae 0,4% 0,3%
g Leptotrichia 0,3% 0,4% s Prevotella sp. oral taxon 781 0,4% 0,4%
g Selenomonas 0,3% 0,6% s Ruminococcus sp. 653 0,4% 0,3%
s Actinomyces israelii 0,3% 0,1% s Streptococcus sp. oral taxon 071
0,4% 0,7%
s Dialister invisus 0,3% 0,6% s Granulicatella adiacens 0,4% 0,1%
s Actinobaculum sp. oral taxon 183
0,3% 0,1% s Leptotrichia sp. oral taxon 212 0,4% 0,7%
s Selenomonas sp. oral taxon 146
0,2% 0,6% g Campylobacter 0,4% 0,2%
s Streptococcus sp. oral taxon C54
0,2% 0,4% s Actinomyces cardiffensis 0,4% 0,2%
s Prevotella sp. oral taxon 289 0,2% 0,2% s Tannerella sp. oral taxon BU063 0,3% 0,3%
s Lautropia mirabilis 0,2% 0,1% s Treponema sp. IV:17B:D4B 0,3% 0,2%
s Streptococcus cristatus 0,2% 0,4% s Fusobacterium canifelinum 0,3% 0,6%
s Leptotrichia sp. oral taxon 463 0,2% 0,4% s Selenomonas noxia 0,3% 0,7%
g Capnocytophaga 0,2% 0,1% s Neisseria sp. oral taxon 014 0,3% 0,4%
s Actinomyces dentalis 0,2% 0,1% s Filifactor alocis 0,3% 0,4%
s Actinomyces naeslundii 0,2% 0,1% s Peptoclostridium yurii 0,3% 0,8%
s Prevotella micans 0,2% 0,2% g Bergeyella 0,3% 0,3%
s Prevotella sp. oral taxon 300 0,2% 0,2% s Fretibacterium sp. feline oral taxon 223 0,3% 0,4%
s Granulicatella adiacens 0,2% 0,1% s Tannerella forsythia 0,3% 0,2%
g Alistipes 0,2% 0,1% s Leptotrichia wadei 0,2% 0,4%
s Streptococcus mitis 0,2% 0,3% s Parvimonas sp. oral taxon 393 0,2% 0,6%
s Prevotella enoeca 0,2% 0,2% s Veillonella dispar 0,2% 0,6%
s Actinomyces gerencseriae 0,2% 0,1% s Peptostreptococcus sp. oral taxon 790
0,2% 0,1%
g Brachymonas 0,2% 0,1% g Aggregatibacter 0,2% 0,4%
s Bulleidia extructa 0,2% 0,4% s Leptotrichia sp. oral taxon 462 0,2% 0,3%
s Campylobacter concisus 0,2% 0,1% s Selenomonas sputigena 0,2% 0,4%
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s Slackia exigua 0,1% 0,1% s Leptotrichia sp. oral taxon 217 0,2% 0,3%
s Capnocytophaga sputigena 0,1% 0,1% s Prevotella sp. oral taxon 306 0,2% 0,2%
s Actinomyces sp. oral taxon 448 0,1% 0,1% s Fusobacterium periodonticum 0,2% 0,3%
f Rhodospirillaceae 0,1% 0,2% s Actinomyces oricola 0,2% 0,1%
s Selenomonas sp. oral taxon D75 0,1% 0,3% s
Lachnoanaerobaculum 
saburreum 0,2% 0,2%
g Actinomyces 0,1% 0,1% g Tannerella 0,2% 0,1%
s Prevotella marshii 0,1% 0,1% s Streptococcus sp. oral taxon 070 0,2% 0,3%
s Neisseria flava 0,1% 0,2% s Alloprevotella tannerae 0,2% 0,2%
s Ruminococcus sp. 653 0,1% 0,1% s Herbinix sp. SD1D 0,2% 0,2%
g Dialister 0,1% 0,3% s Actinomyces sp. oral taxon E91
0,2% 0,1%
s Actinomyces georgiae 0,1% 0,1% s Selenomonas sp. oral taxon 126
0,2% 0,4%
s Actinomyces cardiffensis 0,1% 0,0% s Prevotella oulorum 0,2% 0,2%
s Tannerella forsythia 0,1% 0,1% s Prevotella baroniae 0,2% 0,2%
s Schwartzia sp. canine oral taxon 042
0,1% 0,2% s Fretibacterium fastidiosum 0,1% 0,2%
Other 4,2% s Prevotella sp. oral taxon 515 0,1% 0,1%
Unassigned 5024 s Solobacterium moorei 0,1% 0,3%
Filtered 0 s Desulfomicrobium orale 0,1% 0,1%
s Prevotella veroralis 0,1% 0,1%
g Parvimonas 0,1% 0,3%
s Streptococcus cristatus 0,1% 0,2%
g Dialister 0,1% 0,3%
s Dialister invisus 0,1% 0,3%
s Prevotella sp. oral taxon 289 0,1% 0,1%
s Parvimonas micra 0,1% 0,2%
s Actinomyces massiliensis 0,1% 0,1%
s Eggerthia catenaformis 0,1% 0,3%
s Mycoplasma faucium 0,1% 0,0%
Other 3,7%
Unassigned 6014
Filtered 0
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s Corynebacterium matruchotii 22,9% 18,8% s Corynebacterium matruchotii 5,8% 4,8%
s Streptococcus cristatus 3,7% 7,0% s Rickettsia raoultii 4,8% 1,9%
s Granulicatella adiacens 3,6% 1,4% s Porphyromonas endodontalis 3,6% 1,4%
g Fusobacterium 3,6% 6,5% s Fusobacterium nucleatum 3,2% 5,8%
s Capnocytophaga granulosa 3,4% 2,5% s Peptostreptococcus sp. oral taxon 113
3% 1,2%
s Actinomyces naeslundii 3,3% 1,7% s Porphyromonas gingivalis 2,7% 2,3%
s Leptotrichia wadei 3,0% 5,6% g Capnocytophaga 2,3% 1,7%
g Corynebacterium 2,7% 2,2% s Capnocytophaga granulosa 2,3% 1,7%
s Neisseria elongata 2,6% 3,7% s Actinomyces israelii 2% 1,1%
s Corynebacterium sp. oral taxon B00 2,5% 2,1% g Fusobacterium 2% 3,7%
s Campylobacter showae 2,5% 1,2% g Dysgonomonas 2% 0,8%
g Actinomyces 2,4% 1,2% g Treponema 2% 1,3%
s Lachnoanaerobaculum saburreum 1,9% 1,9% s Campylobacter gracilis 2% 1%
s Capnocytophaga sp. oral taxon 332 1,7% 1,3% s Leptotrichia hofstadii 1,8% 3,4%
g Leptotrichia 1,7% 3,1% s Actinomyces sp. oral taxon 178 1,8% 0,9%
s Capnocytophaga sp. oral taxon 329 1,6% 1,2% s
Actinobaculum sp. oral taxon 
183 1,8% 1,1%
s Tannerella sp. oral taxon BU063 1,5% 1,2% s Leptotrichia buccalis 1,8% 3,3%
s Porphyromonas sp. oral taxon 279 1,4% 1,2% s Streptococcus mutans 1,7% 3,2%
g Porphyromonas 1,2% 1,1% g Selenomonas 1,6% 4,1%
s Actinomyces sp. oral taxon 170 1,2% 0,6% s Alloprevotella tannerae 1,4% 1,6%
s Leptotrichia sp. oral taxon 225 1,1% 2,1% s Capnocytophaga sp. oral taxon 329
1,4% 1%
s Johnsonella sp. oral taxon 166 1,1% 0,4% s Pseudoramibacter alactolyticus
1,3% 0,5%
g Prevotella 1,0% 1,1% g Prevotella 1,3% 1,4%
s Capnocytophaga gingivalis 1,0% 0,7% s Prevotella sp. oral taxon 317 1,2% 1,2%
s Eikenella corrodens 0,9% 0,4% s Streptococcus sp. oral taxon C54
1,1% 2,1%
s Actinomyces sp. 'ARUP UnID 58'
0,9% 0,5% s Actinomyces sp. oral taxon 449
1,1% 0,6%
g Streptococcus 0,9% 1,6% s Leptotrichia wadei 1,1% 2%
s Campylobacter gracilis 0,8% 0,4% s Porphyromonas catoniae 1,1% 0,9%
s Lautropia mirabilis 0,8% 0,3% s Lautropia mirabilis 1% 0,4%
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s Capnocytophaga sp. oral taxon 336 0,8% 0,6% s
Fusobacterium sp. oral taxon 
A11 0,9% 1,7%
s Actinomyces sp. oral taxon 178 0,8% 0,4% s Campylobacter showae 0,9% 0,4%
g Capnocytophaga 0,8% 0,6% s Treponema denticola 0,9% 0,6%
s Streptococcus sp. oral taxon C54 0,8% 1,4% s Veillonella parvula 0,8% 2,1%
s Prevotella sp. 8404125 0,7% 0,8% s Actinomyces sp. oral taxon D05 0,8% 0,4%
g Selenomonas 0,7% 1,7% s Treponema socranskii 0,8% 0,5%
s Prevotella sp. oral taxon 317 0,6% 0,6% s Prevotella oris 0,8% 0,8%
s Fusobacterium nucleatum 0,6% 1,0% s Capnocytophaga gingivalis 0,8% 0,6%
s Veillonella parvula 0,5% 1,3% s Prevotella sp. oral taxon 303 0,8% 0,8%
s Actinomyces dentalis 0,5% 0,3% g Streptococcus 0,8% 1,4%
s Actinomyces sp. oral taxon E91
0,5% 0,2% g Olsenella 0,8% 0,4%
s Campylobacter concisus 0,5% 0,2% s Lachnoanaerobaculum saburreum
0,7% 0,8%
s Propionibacterium propionicum 0,5% 0,4% s Eikenella corrodens 0,7% 0,3%
s Fusobacterium periodonticum 0,5% 0,8% s Actinomyces sp. 'ARUP UnID 71'
0,7% 0,4%
s Streptococcus sanguinis 0,5% 0,9% s Aggregatibacter segnis 0,7% 0,9%
s Selenomonas noxia 0,5% 1,2% g Tannerella 0,7% 0,6%
f Lachnospiraceae 0,5% 0,5% s Campylobacter sp. oral taxon G43 0,7% 0,3%
s Leptotrichia hofstadii 0,4% 0,8% s Streptococcus cristatus 0,6% 1,2%
s Leptotrichia sp. oral taxon 215 0,4% 0,7% s Streptococcus mitis 0,6% 1,1%
s Prevotella intermedia 0,3% 0,3% s Streptococcus sp. oral taxon 070 0,6% 1,1%
s Leptotrichia sp. oral taxon 217 0,3% 0,6% s Selenomonas sp. oral taxon G00 0,5% 1,4%
s Streptococcus sp. oral taxon 071 0,3% 0,6% s Tannerella forsythia 0,5% 0,4%
s Actinomyces israelii 0,3% 0,2% s Fretibacterium sp. feline oral taxon 223 0,5% 0,7%
s Alloprevotella sp. oral taxon 473 0,3% 0,4% s Capnocytophaga sputigena 0,5% 0,4%
s Kingella oralis 0,3% 0,1% s Desulfomicrobium orale 0,5% 0,4%
s Aggregatibacter sp. oral taxon 458 0,3% 0,6% s Kingella oralis 0,5% 0,2%
s Porphyromonas endodontalis 0,3% 0,1% s Capnocytophaga sp. oral taxon 332 0,5% 0,4%
s Porphyromonas sp. oral taxon 277
0,3% 0,2% s Actinomyces massiliensis 0,5% 0,3%
o Lactobacillales 0,3% 0,4% s Porphyromonas sp. oral taxon 278
0,5% 0,4%
s Lachnoclostridium jejuense 0,3% 0,3% s Leptotrichia sp. oral taxon 217
0,5% 0,9%
s Actinobaculum sp. oral taxon 183
0,3% 0,2% s Odoribacter denticanis 0,5% 0,4%
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s Prevotella sp. oral taxon 781 0,3% 0,3% s Lachnoclostridium phytofermentans 0,5% 0,5%
g Alistipes 0,3% 0,2% s Tannerella sp. oral taxon BU063 0,4% 0,3%
s Leptotrichia buccalis 0,3% 0,5% s Corynebacterium sp. oral taxon B00 0,4% 0,4%
s Kingella denitrificans 0,3% 0,1% s Neisseria bacilliformis 0,4% 0,6%
g Olsenella 0,3% 0,1% s Parasporobacterium paucivorans 0,4% 0,4%
s Actinomyces sp. 'ARUP UnID 56' 0,3% 0,1% s Campylobacter concisus 0,4% 0,2%
s Actinomyces sp. oral taxon E63 0,2% 0,1% s
Capnocytophaga sp. oral 
taxon B29 0,4% 0,3%
g Dysgonomonas 0,2% 0,1% g Actinomyces 0,4% 0,2%
s Bergeyella sp. oral taxon 322 0,2% 0,2% s Fusobacterium sp. oral taxon C10
0,4% 0,7%
s Leptotrichia genomosp. C1 0,2% 0,4% s Actinomyces georgiae 0,4% 0,2%
s Prevotella sp. oral taxon 289 0,2% 0,2% s Capnocytophaga genosp. AHN8471
0,3% 0,2%
g Treponema 0,2% 0,1% s Actinomyces sp. oral taxon 414
0,3% 0,2%
s Aggregatibacter segnis 0,2% 0,2% s Prevotella melaninogenica 0,3% 0,3%
s Treponema sp. oral taxon G85 0,2% 0,1% s Capnocytophaga sp. AHN9576
0,3% 0,2%
s Actinomyces sp. oral taxon 414 0,2% 0,1% s Lachnoclostridium jejuense 0,3% 0,3%
s Catonella morbi 0,2% 0,1% s Prevotella sp. oral taxon 306 0,3% 0,3%
g Campylobacter 0,2% 0,1% s Leptotrichia shahii 0,3% 0,6%
s Actinomyces sp. oral taxon D50 0,2% 0,1% s Prevotella oulorum 0,3% 0,3%
s Porphyromonas sp. oral taxon 284 0,2% 0,2% s Prevotella sp. 8404125 0,3% 0,3%
s Capnocytophaga sp. 0,2% 0,1% s Streptococcus anginosus 0,3% 0,1%
s Porphyromonas sp. oral taxon B43 0,2% 0,1% s Actinomyces dentalis 0,3% 0,1%
g Veillonella 0,2% 0,4% s Capnocytophaga sp. oral taxon E54 0,3% 0,2%
s Streptococcus mitis 0,2% 0,3% s Treponema sp. canine oral taxon 395 0,3% 0,2%
s Prevotella sp. oral taxon 475 0,2% 0,2% s Treponema vincentii 0,3% 0,2%
s Streptococcus sp. oral taxon 064 0,1% 0,3% s Parvimonas micra 0,3% 0,6%
g Cardiobacterium 0,1% 0,2% s Catonella morbi 0,3% 0,2%
s Corynebacterium durum 0,1% 0,1% s Johnsonella ignava 0,2% 0,1%
s Treponema socranskii 0,1% 0,1% s Prevotella veroralis 0,2% 0,3%
g Oribacterium 0,1% 0,1% s Streptococcus gordonii 0,2% 0,5%
g Neisseria 0,1% 0,2% s Campylobacter curvus 0,2% 0,1%
g Aggregatibacter 0,1% 0,2% s Moryella sp. KHD1 0,2% 0,2%
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s Selenomonas sp. oral taxon D75 0,1% 0,3% g Porphyromonas 0,2% 0,2%
s Cardiobacterium hominis 0,1% 0,1% s Treponema maltophilum 0,2% 0,1%
Other 2,3% s Fusobacterium sp. oral taxon 203 0,2% 0,4%
Unassigned 2041 s Selenomonas sp. oral taxon 133 0,2% 0,6%
Filtered 0 s Selenomonas sp. oral taxon 140 0,2% 0,6%
s Propionibacterium propionicum 0,2% 0,2%
s Granulicatella adiacens 0,2% 0,1%
s Actinomyces sp. oral taxon 170
0,2% 0,1%
s Capnocytophaga sp. FVAMC 7623
0,2% 0,2%
s Actinomyces gerencseriae 0,2% 0,1%
s Mycoplasma salivarium 0,2% 0,1%
g Corynebacterium 0,2% 0,1%
s Eubacterium brachy 0,2% 0,4%
s Filifactor alocis 0,2% 0,3%
s Leptotrichia sp. oral taxon 392 0,2% 0,3%
s Fusobacterium periodonticum 0,2% 0,3%
s Leptotrichia trevisanii 0,2% 0,3%
s Sporobacterium olearium 0,2% 0,2%
s Streptococcus sp. oral taxon 058 0,2% 0,3%
s Prevotella maculosa 0,2% 0,2%
s Johnsonella sp. oral taxon 166 0,2% 0,1%
s Desulfobulbus sp. oral taxon 041 0,2% 0,1%
s Selenomonas infelix 0,1% 0,4%
s Actinomyces sp. oral taxon 448 0,1% 0,1%
s Selenomonas sputigena 0,1% 0,3%
s Bacteroides heparinolyticus 0,1% 0,2%
s Prevotella salivae 0,1% 0,1%
s Prevotella sp. oral taxon 300 0,1% 0,1%
s Campylobacter rectus 0,1% 0%
s Cardiobacterium hominis 0,1% 0,1%
s Lachnoanaerobaculum cf. saburreum oral strain C27KA
0,1% 0,1%
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s Actinomyces meyeri 0,1% 0,1%
s Prevotella sp. oral taxon 289 0,1% 0,1%
s Actinomyces naeslundii 0,1% 0,1%
s Flexilinea flocculi 0,1% 0,1%
s Mogibacterium timidum 0,1% 0,2%
s Selenomonas sp. oral taxon E57 0,1% 0,3%
Other 3,2%
Unassigned 5559
Filtered 0
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s Streptococcus anginosus 13,2% 5,0% s Campylobacter showae 6,7% 3,5%
g Prevotella 7,9% 8,0% g Dysgonomonas 4,5% 1,9%
g Streptococcus 4,1% 7,6% s Porphyromonas gingivalis 4,2% 3,8%
g Actinomyces 3,4% 1,7% g Streptococcus 3,2% 6,4%
s Aggregatibacter segnis 3,0% 3,5% s Porphyromonas endodontalis 2,9% 1,2%
s Veillonella parvula 2,8% 7,0% s Lautropia mirabilis 2,4% 1,0%
g Campylobacter 2,8% 1,4% s Capnocytophaga sp. oral taxon 329 2,3% 1,8%
s Peptostreptococcus stomatis 2,6% 1,0% g Corynebacterium 2,3% 2,0%
s Alloprevotella tannerae 2,6% 2,9% s Corynebacterium sp. oral taxon B00 2,2% 1,9%
s Leptotrichia sp. oral taxon 498 2,3% 4,1% s Johnsonella sp. oral taxon 166 2,1% 0,9%
g Fusobacterium 2,2% 3,9% g Leptotrichia 1,9% 3,7%
s Porphyromonas gingivalis 2,0% 1,6% g Fusobacterium 1,8% 3,5%
s Campylobacter gracilis 2,0% 0,9% s Fusobacterium nucleatum 1,8% 3,4%
g Dysgonomonas 1,8% 0,7% s Actinomyces sp. oral taxon G84
1,7% 0,9%
s Corynebacterium matruchotii 1,7% 1,4% g Treponema 1,6% 1,1%
s Rickettsia raoultii 1,6% 0,6% g Alistipes 1,5% 1,0%
s Tannerella sp. oral taxon BU063 1,6% 1,2% s Neisseria elongata 1,5% 2,3%
s Neisseria elongata 1,6% 2,2% s Prevotella intermedia 1,5% 1,5%
s Prevotella sp. oral taxon 317 1,5% 1,5% o Burkholderiales 1,4% 2,0%
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s Capnocytophaga sp. oral taxon 329 1,5% 1,0% s Actinomyces naeslundii 1,4% 0,8%
s Fusobacterium nucleatum 1,3% 2,2% s Propionibacterium propionicum 1,4% 1,2%
s Campylobacter showae 1,3% 0,6% s Eikenella corrodens 1,3% 0,5%
g Olsenella 1,2% 0,6% s Lautropia sp. oral taxon A94 1,2% 0,5%
s Prevotella oris 1,0% 1,0% s Capnocytophaga gingivalis 1,2% 0,9%
g Selenomonas 1,0% 2,5% s Leptotrichia buccalis 1,2% 2,3%
s Porphyromonas endodontalis 1,0% 0,4% s Lachnoanaerobaculum saburreum 1,2% 1,3%
s Actinomyces naeslundii 1,0% 0,5% s Catonella morbi 1,1% 0,9%
s Leptotrichia wadei 0,9% 1,7% s Peptostreptococcus stomatis 1,1% 0,5%
s Granulicatella adiacens 0,9% 0,4% s Leptotrichia sp. oral taxon 392 1,0% 2,0%
s Atopobium rimae 0,9% 0,4% g Tannerella 1,0% 0,8%
g Neisseria 0,8% 1,1% s Atopobium rimae 1,0% 0,5%
s Eikenella corrodens 0,8% 0,3% s Streptococcus sanguinis 0,9% 1,8%
s Treponema socranskii 0,7% 0,5% s Rickettsia raoultii 0,8% 0,3%
g Treponema 0,7% 0,5% s Actinomyces sp. oral taxon 525 0,8% 0,4%
s Capnocytophaga granulosa 0,7% 0,5% s Prevotella sp. oral taxon 781 0,8% 0,8%
s Lachnoanaerobaculum cf. saburreum oral strain C27KA 0,7% 0,7% s Actinomyces israelii 0,7% 0,4%
s Prevotella baroniae 0,7% 0,7% g Prevotella 0,7% 0,8%
s Leptotrichia sp. oral taxon 392 0,6% 1,1% s Treponema socranskii 0,7% 0,5%
f Lachnospiraceae 0,6% 0,6% s Prevotella sp. oral taxon 472 0,7% 0,8%
s Leptotrichia sp. 'ARUP UnID 389' 0,6% 1,0% s Campylobacter gracilis 0,7% 0,4%
s Streptococcus sp. oral taxon C54 0,5% 0,9% g Selenomonas 0,7% 1,9%
s Capnocytophaga sp. AHN9576 0,5% 0,3% g Capnocytophaga 0,7% 0,5%
s Parvimonas micra 0,5% 1,1% s Actinomyces dentalis 0,7% 0,4%
s Catonella morbi 0,5% 0,3% s Actinomyces sp. oral taxon 178 0,7% 0,4%
s Actinomyces sp. oral taxon 446 0,4% 0,2% f Lachnospiraceae 0,7% 0,7%
s Anaeroglobus geminatus 0,4% 1,1% s Prevotella sp. oral taxon 317 0,7% 0,7%
g Porphyromonas 0,4% 0,3% s Actinomyces oricola 0,6% 0,4%
f Rhodospirillaceae 0,4% 0,6% s Lachnoclostridium jejuense 0,6% 0,7%
s Porphyromonas sp. oral taxon 278 0,4% 0,3% s Lachnoanaerobaculum cf. saburreum oral strain C27KA
0,6% 0,7%
s Actinomyces israelii 0,4% 0,2% s Capnocytophaga sp. 'ARUP UnID 182'
0,6% 0,4%
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g Corynebacterium 0,4% 0,3% s Selenomonas noxia 0,6% 1,6%
s Selenomonas noxia 0,4% 0,9% g Campylobacter 0,6% 0,3%
s Actinomyces sp. 'ARUP UnID 56' 0,3% 0,2% s Actinomyces sp. oral taxon E91 0,5% 0,3%
s Capnocytophaga sp. oral taxon E54 0,3% 0,2% g Olsenella 0,5% 0,3%
s Selenomonas sputigena 0,3% 0,8% f Rhodospirillaceae 0,5% 0,7%
s Prevotella sp. oral taxon 306 0,3% 0,3% s Actinomyces sp. oral taxon 449 0,5% 0,3%
s Magnetofaba australis 0,3% 0,3% s Capnocytophaga granulosa 0,5% 0,4%
s Lachnoanaerobaculum saburreum 0,3% 0,3% g Actinomyces 0,5% 0,3%
s Fretibacterium sp. feline oral taxon 223
0,3% 0,4% s Leptotrichia sp. oral taxon B57 0,5% 0,9%
s Prevotella veroralis 0,3% 0,3% s Actinomyces sp. oral taxon 414
0,4% 0,2%
s Bergeyella sp. oral taxon 322 0,3% 0,3% s Granulicatella adiacens 0,4% 0,2%
s Streptococcus sp. oral taxon 058 0,3% 0,5% s Lachnoclostridium phytofermentans
0,4% 0,5%
s Streptococcus cristatus 0,3% 0,5% s Porphyromonas catoniae 0,4% 0,4%
s Actinomyces sp. 'ARUP UnID 92' 0,3% 0,1% s Fusobacterium periodonticum 0,4% 0,7%
s Prevotella marshii 0,3% 0,3% s Aggregatibacter segnis 0,4% 0,5%
s Aggregatibacter sp. oral taxon 513 0,3% 0,5% s Treponema maltophilum 0,4% 0,3%
s Solobacterium moorei 0,3% 0,6% s Leptotrichia wadei 0,4% 0,7%
s Selenomonas infelix 0,2% 0,6% s Magnetofaba australis 0,4% 0,3%
s Slackia exigua 0,2% 0,1% s Prevotella baroniae 0,3% 0,4%
s Prevotella micans 0,2% 0,2% s Leptotrichia sp. oral taxon 212 0,3% 0,7%
s Selenomonas dianae 0,2% 0,6% s Streptococcus sp. oral taxon C54 0,3% 0,6%
s Fretibacterium fastidiosum 0,2% 0,3% s Capnocytophaga sp. AHN10044 0,3% 0,2%
s Alloprevotella rava 0,2% 0,2% s Fretibacterium sp. feline oral taxon 223 0,3% 0,5%
s Mogibacterium timidum 0,2% 0,4% s Capnocytophaga sputigena 0,3% 0,2%
s Parasporobacterium paucivorans 0,2% 0,2% s Campylobacter concisus 0,3% 0,2%
g Megasphaera 0,2% 0,6% s Prevotella oulorum 0,3% 0,3%
s Eubacterium sp. oral strain A35MT 0,2% 0,4% s Prevotella sp. oral taxon 526 0,3% 0,3%
g Dialister 0,2% 0,5% s Fusobacterium hwasookii 0,3% 0,5%
s Capnocytophaga gingivalis 0,2% 0,1% g Bergeyella 0,3% 0,3%
s Actinomyces dentalis 0,2% 0,1% s Capnocytophaga sp. oral taxon 323
0,3% 0,2%
s Kingella denitrificans 0,2% 0,1% s Actinomyces massiliensis 0,2% 0,1%
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s Prevotella oralis 0,2% 0,2% s Tannerella sp. oral taxon BU063 0,2% 0,2%
s Prevotella sp. oral taxon 781 0,2% 0,2% s Actinomyces sp. oral taxon 172 0,2% 0,1%
s Streptococcus gordonii 0,2% 0,3% s Bergeyella sp. AF14 0,2% 0,3%
s Filifactor alocis 0,2% 0,3% s Prevotella sp. oral taxon C29 0,2% 0,3%
s Dialister invisus 0,2% 0,4% s Peptostreptococcus sp. oral taxon 113 0,2% 0,1%
s Actinomyces georgiae 0,2% 0,1% s Actinomyces cardiffensis 0,2% 0,1%
s Herbinix sp. SD1D 0,2% 0,2% s Prevotella oris 0,2% 0,2%
s Kingella oralis 0,2% 0,1% s Campylobacter sp. oral taxon 044
0,2% 0,1%
s Actinomyces sp. oral taxon E91 0,2% 0,1% s Eubacterium sp. 'Smarlab BioMol-2301231'
0,2% 0,4%
g Atopobium 0,2% 0,1% s Selenomonas infelix 0,2% 0,5%
s Streptococcus mitis 0,1% 0,3% s Actinobaculum sp. oral taxon 183
0,2% 0,1%
g Veillonella 0,1% 0,4% s Veillonella parvula 0,2% 0,4%
s Actinomyces massiliensis 0,1% 0,1% s Bosea sp. R-38307 0,2% 0,1%
s Prevotella maculosa 0,1% 0,1% s Prevotella loescheii 0,2% 0,2%
s Leptotrichia sp. oral taxon 215 0,1% 0,2% s Mucinivorans hirudinis 0,2% 0,1%
s Propionibacterium propionicum 0,1% 0,1% s Treponema vincentii 0,2% 0,1%
s Selenomonas sp. oral taxon E83 0,1% 0,3% s Prevotella sp. oral taxon 289 0,2% 0,2%
s Leptotrichia sp. oral taxon 212 0,1% 0,2% s Herbinix sp. SD1D 0,2% 0,2%
s Tannerella forsythia 0,1% 0,1% s Streptococcus sp. oral taxon 058 0,2% 0,3%
s Streptococcus sanguinis 0,1% 0,3% s Peptoclostridium yurii 0,2% 0,5%
g Mogibacterium 0,1% 0,2% s Leptotrichia sp. oral taxon 498 0,2% 0,3%
s Eubacterium saphenum 0,1% 0,3% s Tannerella forsythia 0,2% 0,1%
g Bergeyella 0,1% 0,1% s Selenomonas sp. oral taxon 478 0,2% 0,5%
s Prevotella oulorum 0,1% 0,1% s Eubacterium sp. oral taxon 081 0,2% 0,3%
s Johnsonella sp. oral taxon 166 0,1% 0,0% s Filifactor alocis 0,2% 0,3%
s Treponema sp. IV:17B:D4B 0,1% 0,1% s Dialister invisus 0,2% 0,4%
s Cryptobacterium curtum 0,1% 0,1% s Selenomonas sputigena 0,2% 0,4%
g Cardiobacterium 0,1% 0,1% s Actinomyces sp. oral taxon 171
0,2% 0,1%
s Treponema maltophilum 0,1% 0,1% s Leptotrichia sp. oral taxon 462 0,2% 0,3%
s Fusobacterium hwasookii 0,1% 0,2% s Atopobium sp. DMCT15023 0,1% 0,1%
s Lautropia mirabilis 0,1% 0,0% s Prevotella micans 0,1% 0,2%
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Other 2,9% s Prevotella sp. oral taxon 314 0,1% 0,2%
Unassigned 2441 s Parasporobacterium paucivorans 0,1% 0,2%
Filtered 0 s Selenomonas dianae 0,1% 0,4%
s Prevotella sp. E9 42 0,1% 0,2%
s Treponema sp. IV:17B:D4B 0,1% 0,1%
s Bergeyella sp. oral taxon 322 0,1% 0,2%
s Streptococcus mitis 0,1% 0,3%
s Treponema sp. oral taxon 247 0,1% 0,1%
s Prevotella marshii 0,1% 0,1%
s Tannerella sp. oral taxon 808 0,1% 0,1%
s Eubacterium sp. oral strain A35MT
0,1% 0,2%
s Capnocytophaga sp. 'ARUP UnID 185'
0,1% 0,1%
f Flavobacteriaceae 0,1% 0,1%
s Prevotella maculosa 0,1% 0,1%
s Treponema medium 0,1% 0,1%
s Slackia exigua 0,1% 0,1%
s Parvimonas micra 0,1% 0,2%
g Cardiobacterium 0,1% 0,1%
g Brachymonas 0,1% 0,1%
s Fusobacterium sp. oral taxon A42 0,1% 0,2%
s Propionivibrio sp. oral taxon C33 0,1% 0,1%
s Porphyromonas sp. oral taxon 279 0,1% 0,1%
s Eubacterium sp. oral taxon G32 0,1% 0,2%
s Anaeroglobus geminatus 0,1% 0,3%
s Sporobacterium olearium 0,1% 0,1%
s Schwartzia sp. canine oral taxon 042 0,1% 0,3%
Other 4,0%
Unassigned 4846
Filtered 0
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The following plots represent the different results for each sample in different level of taxonomy 
(Phylum, class and order because higher level plots give a more coarse grained view on the 
data than lower level plots). 
PHYLUM
Total F01 PD F02 PD F03 PD F04 PD F05 PD F06 PD
Legend Taxonomy
count % % % % % % %
  Unclassified;Other 10029 4% 4% 5% 1% 4% 3% 4%
  k__Bacteria;p__ 55 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Actinobacteria 54308 19% 7% 16% 40% 18% 11% 17%
  k__Bacteria;p__Bacteroidetes 77926 28% 34% 28% 19% 29% 27% 29%
  k__Bacteria;p__Chloroflexi 77 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Firmicutes 54846 19% 14% 19% 17% 19% 33% 18%
  k__Bacteria;p__Fusobacteria 33774 12% 18% 11% 12% 12% 8% 10%
  k__Bacteria;p__Proteobacteria 40847 14% 13% 18% 10% 13% 15% 19%
  k__Bacteria;p__Spirochaetes 9937 4% 9% 2% 1% 4% 2% 3%
  k__Bacteria;p__Synergistetes 1594 1% 2% 0% 0% 1% 1% 0%
  k__Bacteria;p__Tenericutes 248 0% 0% 0% 0% 0% 0% 0%
 
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CLASS
Total F01 PD F02 PD F03 PD F04 PD F05 PD F06 PD
Legend Taxonomy
count % % % % % % %
  Unclassified;Other;Other 10029 4% 4% 5% 1% 4% 3% 4%
  k__Bacteria;p__;c__ 55 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Actinobacteria;c__Actinobacteria 50912 18% 6% 15% 40% 17% 9% 15%
  k__Bacteria;p__Actinobacteria;c__Coriobacteriia 3396 1% 1% 1% 0% 1% 3% 2%
  k__Bacteria;p__Bacteroidetes;c__Bacteroidia 58401 21% 32% 21% 10% 20% 23% 22%
  k__Bacteria;p__Bacteroidetes;c__Flavobacteriia 19525 7% 2% 8% 10% 9% 4% 7%
  k__Bacteria;p__Chloroflexi;c__Anaerolineae 77 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Firmicutes;c__ 9 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Firmicutes;c__Bacilli 22057 8% 2% 7% 10% 6% 20% 5%
  k__Bacteria;p__Firmicutes;c__Clostridia 20683 7% 8% 8% 4% 8% 6% 10%
  k__Bacteria;p__Firmicutes;c__Erysipelotrichia 377 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Firmicutes;c__Negativicutes 10161 4% 2% 5% 2% 4% 7% 3%
  k__Bacteria;p__Firmicutes;c__Tissierellia 1559 1% 2% 1% 0% 0% 1% 0%
  k__Bacteria;p__Fusobacteria;c__Fusobacteriia 33774 12% 18% 11% 12% 12% 8% 10%
  k__Bacteria;p__Proteobacteria;c__Alphaproteobacteria 6594 2% 4% 1% 0% 5% 2% 2%
  k__Bacteria;p__Proteobacteria;c__Betaproteobacteria 13501 5% 1% 8% 5% 3% 4% 8%
  k__Bacteria;p__Proteobacteria;c__Deltaproteobacteria 471 0% 0% 0% 0% 1% 0% 0%
  k__Bacteria;p__Proteobacteria;c__Epsilonproteobacteria 15972 6% 7% 6% 4% 4% 6% 8%
 
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  k__Bacteria;p__Proteobacteria;c__Gammaproteobacteria 4309 2% 1% 3% 1% 1% 3% 1%
  k__Bacteria;p__Spirochaetes;c__Spirochaetia 9937 4% 9% 2% 1% 4% 2% 3%
  k__Bacteria;p__Synergistetes;c__Synergistia 1594 1% 2% 0% 0% 1% 1% 0%
  k__Bacteria;p__Tenericutes;c__Mollicutes 248 0% 0% 0% 0% 0% 0% 0%
ORDER
Total F01 PD F02 PD F03 PD F04 PD F05 PD F06 PD
Legend Taxonomy
count % % % % % % %
  Unclassified;Other;Other;Other 10029 4% 4% 5% 1% 4% 3% 4%
  k__Bacteria;p__;c__;o__ 55 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Actinobacteria;c__Actinobacteria;o__Actinomycetales 24472 9% 3% 9% 11% 11% 6% 10%
  k__Bacteria;p__Actinobacteria;c__Actinobacteria;o__Corynebacteriales 24493 9% 2% 4% 28% 6% 2% 4%
  k__Bacteria;p__Actinobacteria;c__Actinobacteria;o__Micrococcales 124 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Actinobacteria;c__Actinobacteria;o__Propionibacteriales 1823 1% 0% 1% 1% 0% 0% 1%
  k__Bacteria;p__Actinobacteria;c__Coriobacteriia;o__Coriobacteriales 3098 1% 1% 1% 0% 1% 2% 2%
  k__Bacteria;p__Actinobacteria;c__Coriobacteriia;o__Eggerthellales 298 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales 58401 21% 32% 21% 10% 20% 23% 22%
  k__Bacteria;p__Bacteroidetes;c__Flavobacteriia;o__Flavobacteriales 19525 7% 2% 8% 10% 9% 4% 7%
  k__Bacteria;p__Chloroflexi;c__Anaerolineae;o__Anaerolineales 77 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Firmicutes;c__;o__ 9 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Firmicutes;c__Bacilli;o__ 12 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Firmicutes;c__Bacilli;o__Lactobacillales 22045 8% 2% 7% 10% 6% 20% 5%
 
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The carotid specimens of all 6 patients revealed evidence of severe atherosclerosis; the plaques 
showed a calcified core with frequent circumferential fatty deposit. Not enough DNA of 
periodontal bacteria was detected in any of the carotid samples using the same methods.  
Comparing the oral microbiome we found a group of bacteria present in all patient showed in the 
following charts with percentage. 
  k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales 20683 7% 8% 8% 4% 8% 6% 10%
  k__Bacteria;p__Firmicutes;c__Erysipelotrichia;o__Erysipelotrichales 377 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Firmicutes;c__Negativicutes;o__Selenomonadales 10161 4% 2% 5% 2% 4% 7% 3%
  k__Bacteria;p__Firmicutes;c__Tissierellia;o__Tissierellales 1559 1% 2% 1% 0% 0% 1% 0%
  k__Bacteria;p__Fusobacteria;c__Fusobacteriia;o__Fusobacteriales 33774 12% 18% 11% 12% 12% 8% 10%
  k__Bacteria;p__Proteobacteria;c__Alphaproteobacteria;o__ 186 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Proteobacteria;c__Alphaproteobacteria;o__Magnetococcales 276 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Proteobacteria;c__Alphaproteobacteria;o__Rhizobiales 1569 1% 3% 1% 0% 0% 0% 0%
  k__Bacteria;p__Proteobacteria;c__Alphaproteobacteria;o__Rhodospirillales 486 0% 0% 0% 0% 0% 0% 1%
  k__Bacteria;p__Proteobacteria;c__Alphaproteobacteria;o__Rickettsiales 4035 1% 1% 0% 0% 5% 2% 1%
  k__Bacteria;p__Proteobacteria;c__Alphaproteobacteria;o__Sneathiellales 42 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Proteobacteria;c__Betaproteobacteria;o__Burkholderiales 5896 2% 0% 5% 1% 1% 0% 5%
  k__Bacteria;p__Proteobacteria;c__Betaproteobacteria;o__Neisseriales 7530 3% 1% 3% 4% 2% 4% 3%
  k__Bacteria;p__Proteobacteria;c__Betaproteobacteria;o__Rhodocyclales
75 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Proteobacteria;c__Deltaproteobacteria;o__Desulfobacterales
79 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Proteobacteria;c__Deltaproteobacteria;o__Desulfovibrionales
392 0% 0% 0% 0% 1% 0% 0%
  k__Bacteria;p__Proteobacteria;c__Epsilonproteobacteria;o__Campylobacterales 15972 6% 7% 6% 4% 4% 6% 8%
  k__Bacteria;p__Proteobacteria;c__Gammaproteobacteria;o__Cardiobacteriales 409 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Proteobacteria;c__Gammaproteobacteria;o__Pasteurellales 3900 1% 1% 3% 1% 1% 3% 1%
  k__Bacteria;p__Spirochaetes;c__Spirochaetia;o__Spirochaetales 9937 4% 9% 2% 1% 4% 2% 3%
  k__Bacteria;p__Synergistetes;c__Synergistia;o__Synergistales 1594 1% 2% 0% 0% 1% 1% 0%
  k__Bacteria;p__Tenericutes;c__Mollicutes;o__Acholeplasmatales 56 0% 0% 0% 0% 0% 0% 0%
  k__Bacteria;p__Tenericutes;c__Mollicutes;o__Mycoplasmatales 192 0% 0% 0% 0% 0% 0% 0%
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 SPECIESGROUPFAMILYORDERCLASSPHYLUMKINGDOM
BACTERIA ACTINOBACTERIA
ACTINOBACTERIA
ACTINOMYCELATES ACTINOMICETACEAE
ACTINOBACULUM SP.	ORAL	TAXON	 183	(0,5%)
ACTINOMYCES
(1,4%)
DENTALIS	 (0,5%)
ISRAELII	 (0,7%)
MASSILENSIS	 (0,2%)
NAESLUNDII	 (1,7%)
SP.	ORAL	TAXON	
E91(0,2%)
CORINOBACTERIALES CORYNEBACTERIACEAE CORYNEBACTERIUM
(1,3%)
MATRUCHOTII	 (6,1%)
SP.	ORAL	TAXON	 800	
(1,2%)
PROPIONIBACTERIALES PROPIONIBACTERIACEAE PROPIONIBACTERIUM PROPIONICUM	 (0,6%)
CORIOBACTERIA
CORIOBACTERIALES ATOPOBIACEAE OLSENELLA	 (0,6%)
EGGERTHELLALES EGGERTHELLACEAE SLACKIA EXIGUA	 (0,1%)
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 SPECIESGROUPFAMILYORDERCLASSPHYLUMKINGDOM
BACTERIA BACTERIOIDETES
BACTERIOIDIA BACTEROIDALES
PORPHYROMONAD
ACEAE
DYSGONOMONAS	
(1,9%)
PORPHYROMONAS
(0,6%)
ENDODONTALIS	
(3,4%)
GINGIVALIS	 (1,5%)
SP.	ORAL	TAXON	
278	(0,2%)
TANNERELLA
FORSYTHIA	 (0,2%)
SP.	ORAL	TAXON	
BUO63	(1%)
PREVOTELLACEAE
ALLOPREVOTELLA SP.	ORAL	TAXON	308	(0,01%)
PREVOTELLA
(2,3%)
MACULOSA	 (0,1%)
MARSHII	 (0,1%)
ORALIS	 (0,1%)
ORIS	 (0,8%)
OULORUM	 (0,2%)
SP.	ORAL	TAXON	
289	(0,1%)
SP.	ORAL	TAXON	
317	(1,1%)
SP.	ORAL	TAXON	
781	(0,3%)
RIKENELLACEAE
FLAVOBACTERIIA FLAVOBACTERIALES
FLAVOBACTERIACE
AE
CAPNOCYTOPHAG
A
(0,8%)
GINGIVALIS	 (0,7%)
GRANULOSA	
(1,6%)
SP.ORAL	TAXON	
329	(1,7%)
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 SPECIESGENUSFAMILYORDERCLASSPHYLUMKINGDOM
BACTERIA
SYNERGISTETES SYNERGISTIA SYNERGISTALES
SYNERGISTACEA
E
FRETIBACTERIU
M
FASTIDIOSUM	
(0,2%)
SP.	FELINE	 ORAL	
TAXON	 223	
(0,3%)
FUSOBACTERIA FUSOBACTERIIA FUSOBACTERIALES
FUSOBACTERIAC
EAE
FUSOBACTERIU
M
(2,4%)
NUCLEATUM	
(2,4%)
PERIODONTICU
M	(0,2%)
LEPTOTRICHIACE
AE LEPTOTRICHIA
(0,8%)
SP.	ORAL	TAXON	
392	(0,5%)
SP.	ORAL	TAXON	
462	(0,2%)
WADEI	 (1%)
SPIROCHAETES SPIROCHAETIA SPIROCHAETALES
SPIROCHAETACE
A TREPONEMA
(1,7%)
MALTOPHILUM	
(0,2%)
SOCRANSKII	
(0,9%)
PROTEOBACTERI
A
ALPHAPROTEOB
ACTERIA
RHODOSPIRILLA
LES
RHODOSPIRILLA
CEAE	 (0,2%)
RICKETTSIALES RICKETTSIACEAE RICKETTSIA RAOULTII	 (1,4%)
BETAPROTEOBA
CTERIA
BURKHOLDERIAL
ES
BURKHOLDERIA
CEAE LAUTROPIA
MIRABILIS	
(1,5%)
COMAMONADA
CEAE
BRACHYMONAS	
(0,1%)
NEISSERIALES NEISSERIACEAE
EIKENELLA CORRODENS	(0,8%)
NEISSERIA
(0,1%)
ELONGATA	
(1,1%)
EPSILONBACTERI
A
CAMPYLOBACTE
RALES
CAMPYLOBACTE
RACEAE
CAMPYLOBACTE
R
(0,5%)
GRACILIS	(1,1%)
SHOWAE	 (2,7%)
GAMMAPROTEO
BACTERIA
CARDIOBACTERI
ALES
CARDIOBACTERI
ACEAE
CARDIOBACTERI
UM	 (0,1%)
PASTEURELLALE
S
PASTEURELLACE
AE
AGGREGATIBAC
TER SEGNIS	 (1,1%)
TERRAHAEMOP
HILUS
AROMATICUVOR
ANS	 (0,01%)
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 SPECIESGENUSFAMILYORDERCLASSPHYLUMKINGDOM
BACTERIA FIRMICUTES
BACILLI LACTOBACILLALES
CARNOBACT
ERIACEAE
GRANULICAT
ELLA
ADIACENS	
(1%)
STREPTOCOC
CACEAE
STREPTOCOC
CUS
(1,9%)
CRISTATUS	
(0,9%)
SANGUINIS	
(0,4%)
MITIS	 (0,2%)
SP.	ORAL	
TAXON	 C54	
(0,7%)
CLOSTRIDIA CLOSTRIDIALES
CLOSTRIDIAL
ES	 FAMILY	
XIII	
INCERTAE	
SEDIS
MOGIBACTE
RIUM
TIMIDUM	
(0,1%)
EUBACTERIA
CEAE
EUBACTERIU
M
BRACHY	
(0,3%)
SP.ORAL	STRAIN	
A35MT	(0,1%)
SP.	ORAL	TAXON	 G75	
(0,01%)
LACHNOSPIR
ACEAE
(0,4%)
CATONELLA MORBI	(0,6%)
LACHNOANA
EROBACULU
M
CF.	SABURREUM	 ORAL	STRAIN	
C27KA	(0,3%)
SABURREUM	
(1%)
LACHNOCLO
STRIDIUM
JEJUENSE	
(0,3%)
MORYELLA SP.	KHD1	(0,1%)
ORIBACTERI
UM	 (0,01%)
PEPTOSTREP
TOCOCCACE
AE
FILIFACTOR ALOCIS	(0,1%)
PEPTOSTREP
TOCOCCUS
STOMATIS	
(1%)
ERYSIPELOTR
ICHIA
ERYSIPELOTR
ICHALES
ERYSIPELOTR
ICHACEAE
SOLOBACTER
IUM
MOOREI	
(0,1%)
NEGATIVICU
TES
SELENOMON
ADALES
VEILLONELLA
CEAE
DIALISTER
(0,1%)
INVISUS	
(0,1%)
SCHWARTIA
SP.	CANINE	
ORAL	TAXON	
042	(0,1%)
SELENOMON
AS
(0,8%)
DIANAE	
(0,1%)
GENOMOSP.	
C2	(0,01%)
NOXIA	
(0,3%)
SPUTIGENA	
(0,2%)
VEILLONELLA PARVULA	(1%)
TISSIERELLIA TISSIERELLALES
PEPTONIPHIL
ACEAE
PARVIMONA
S
MICRA	
(0,5%)
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2.3 DISCUSSION 
Different studies have suggested a possible association between periodontitis and the extent 
and severity of cardiovascular disease[29, 33-35]. However, complete evidence has not been 
established in this field and other studies which questioned this association have been 
published[80-82]. Experimental studies have demonstrated the ability of such periodontal 
pathogens to interact with the endothelial surface and to induce smooth cell proliferation and the 
local release of inflammatory cytokines. Therefore the presence of periodontal bacteria in 
human atherosclerotic plaques may play a role in the initiation, development and progression 
stage of atherosclerosis. 
The present study was first aimed to ascertain the presence of periodontal bacteria DNA in 
carotid atheroma in dentate patients. A total of 6 carotid samples were collected and analyzed 
for 16S Microbiome profiling (region V1-V3) but in none of the atherosclerotic plaque samples 
there was enough DNA of periodontal pathogen detection. We have to remember that in our 
population none of the patient had severe periodontitis. 
Our data agree with Cairo et al[83] but do not concur with the results published by Chiu[56] 
(immunocytochemical investigation; 42% of carotid plaques positive for P Gingivalis), Haraszthy 
et al[17] (PCR amplified 16S rDNA and DNA species-species probes, 30% positive for T. 
Forsythensis, 26% for P. Gingivalis, 18% A Actinomycetemcomitans, 14% for P. Intermedia), 
Taylor-Robinson et al[84] (PCR-amplified 16S rDNA and universal primers, 22% positive for A 
Actinomycetemcomitans and 9% for P. Intermedia) and Ishihara et al[57] (PCR-amplified 16S 
rRNA, 21% positive for P. Gingivalis, 23% for A. Actinomycetemcomitans, 5,9% for T. 
Forsythensis). Such differences among various research works indicate that microbial 
associations in atherosclerotic plaques are highly diverse and variable between individual 
patients.  
These studies identify at least one, but often multiple, periodontal pathogen in atheromatous 
samples, whereas we have no evidence of periodontal bacteria DNA in our sample collection. A 
possible reason for this difference could be the methodology used in different laboratories. An 
alternative hypothesis, even if less probable, could be that the prevalence of periodontal 
bacteria DNA in atheromatous lesions differs due to epidemiological reasons (disease stage, 
 55
nutrition, geographic factors, ethnicity…). However, the presence of bacterial DNA in 
atheromatous plaques still remains a controversial issue.  
The cumulative evidence in the literature supports, but does not prove, a causal association 
between periodontal infection and atherosclerotic cardiovascular disease or its sequelae. A 
number of legitimate concerns have arisen about the nature of this relationship and, indeed, 
about the appropriate definitions for periodontal disease when is thought to be an exposure for 
systemic disease. 
Periodontal pathogens have been shown to contribute directly to atherosclerosis by disrupting 
endothelial cell function, one of the earliest indicators of cardiovascular disease. Oral infection is 
thought to indirectly induce elevated production of inflammatory mediators in the systemic 
circulation and it is clear that the immune mechanisms leading to atherosclerotic plaque pro- 
gression, by oral infection, are complex[25]. Understanding the immune pathways leading to 
disease progression is essential for the future development of anti-inflammatory therapies for 
this chronic disease. Indeed chronic extravasal inflammatory processes may also interact with 
atherosclerotic lesions. For example, is known that patients suffering from chronic infections 
have 4.1 times higher risk to develop carotid atherosclerosis compared to none[85]. The routes 
on how local infections induce systemic effects have been studied extensively in recent years, 
since it became evident that local infections may contribute to the initiation and progression of 
several clinical diseases in humans. The relevant pathways of action are by direct migration of 
bacteria from local biofilms to tissues and organs using the bloodstream or lymphatic vessels, or 
by the local release of inflammatory mediators and pathogenic agents into the bloodstream to 
exert inflammatory reactions in predisposed tissues or organs.  
In conclusion several studies were published that reported the identification of periopathogens in 
atherosclerotic plaques for uncovering the pathological pathways between periodontal and 
atherosclerotic diseases. Bacteria that have been associated with carious lesions were found in 
atherosclerotic plaques as well. However, several studies, as ours, were not able to find 
periopathogens in atherosclerotic plaques, and hence, the transmission of bacteria from the oral 
cavity to atherosclerotic plaques and their direct effects are still under debate[83, 86]. 
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3. CONCLUSIONS 
The critical question of whether periodontal infections are a risk factor for or contribute casually 
to cardiovascular disease remains unanswered. The possibility that periodontal disease and 
cardiovascular disease share common risk factors or are manifestations of a similar underlying 
pathology remains. As mentioned periodontal and cardiovascular disease share common risk 
factors so a correlation between the two would be expected even if a causal link did not exist. 
However, at this point of time, it is difficult to pin point whether it is the stand-alone role of 
individual periodontal pathogen or the total periodontal border as a whole, which contribute 
towards atherosclerosis. Further molecular studies are required to elucidate the role of 
periodontitis inflammation for a better understanding of this association. 
There is, however, no direct peer-reviewed evidence to suggest that treating or preventing 
periodontal infections leads to fewer clinical cardiovascular events. Recommending periodontal 
treatment solely for the purpose of atherosclerotic cardiovascular disease prevention is not 
warranted based on current scientific evidence. Periodontal treatment must be recommended on 
the basis of the value of its benefits for the oral health of patients, recognizing that patients are 
not healthy without good oral health and taking into account American Heart Association 
recommendations[87]. 
It is important also to remember that atherosclerosis has a strong inflammatory component and 
epidemiological evidence suggests that increased levels of systemic inflammation are predictive 
of cardiovascular events and is almost certain that people with periodontal disease have 
elevated levels of systemic inflammatory markers such as C-Reactive Protein. Triggers for this 
enhanced systemic inflammatory response include transient bacteremia and local release of 
bacteria byproducts. 
In conclusion, the results of this study do not support the previous findings that reported a 
frequent presence of periodontal pathogens in carotid atheroma lesions. Our data, therefore, 
tend to exclude a direct correlation between the detection of periodontal bacteria DNA in oral 
lesions and its concomitant presence in carotid atheroma. However, the current evidence 
supporting association raises an important question: “If periodontal infection is suppressed by 
anti-infective intervention, will this result in a decreased risk of cardiovascular disease?” 
Answers to this questions would be clinically meaningful and may more directly implicate 
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periodontal disease as risk factor for cardiovascular disease for his systemic effects. Some 
studies have evaluated the impact of periodontal treatment, with or without antimicrobial therapy, 
on systemic inflammation or endothelial dysfunction and have shown mixed results[88]. 
About our study it is necessary to extend the number of cases to obtain well-founded result. But 
the direction of future research must be primarily to understand mechanisms that can relate 
periodontitis to atherosclerosis, in particular regarding inflammatory cascade. 
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